<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Pharmacol</journal-id><journal-title>BMC Pharmacology</journal-title><issn pub-type="epub">1471-2210</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">18959779</article-id><article-id pub-id-type="pmc">2613135</article-id><article-id pub-id-type="publisher-id">1471-2210-8-18</article-id><article-id pub-id-type="doi">10.1186/1471-2210-8-18</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Bioequivalence study of three ibuprofen formulations after single dose administration in healthy volunteers</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Bramlage</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>peter.bramlage@mailbox.tu-dresden.de</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Goldis</surname><given-names>Adrian</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>peter.bramlage@mailbox.tu-dresden.de</email></contrib></contrib-group><aff id="I1"><label>1</label>Institute for Clinical Pharmacology, Medical Faculty Carl Gustav Carus, Technical University Dresden, Fiedlerstrasse 27, 01307 Dresden, Germany</aff><aff id="I2"><label>2</label>IFE Human Pharmacology SRL, Str. Cornelia Salceanu Nr. 5, 300561 Timisoara, Romania</aff><pub-date pub-type="collection"><year>2008</year></pub-date><pub-date pub-type="epub"><day>29</day><month>10</month><year>2008</year></pub-date><volume>8</volume><fpage>18</fpage><lpage>18</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2210/8/18"></ext-link><history><date date-type="received"><day>11</day><month>6</month><year>2008</year></date><date date-type="accepted"><day>29</day><month>10</month><year>2008</year></date></history><permissions><copyright-statement>Copyright © 2008 Bramlage and Goldis; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2008</copyright-year><copyright-holder>Bramlage and Goldis; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"></ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><sec><title><offsets xml_i="2828" xml_f="2838" txt_i="11" txt_f="21">Background</offsets></title><p><offsets xml_i="2849" xml_f="2951" txt_i="22" txt_f="124">This phase I study was designed to determine the bioavailability and bioequivalence of 400 mg Eudorlin</offsets><sup><offsets xml_i="2956" xml_f="2958" txt_i="124" txt_f="126">® </offsets></sup><offsets xml_i="2964" xml_f="3042" txt_i="126" txt_f="204">extra* (Ibuprofen) in comparison to two reference formulations (400 mg Nurofen</offsets><sup><offsets xml_i="3047" xml_f="3049" txt_i="204" txt_f="206">® </offsets></sup><offsets xml_i="3055" xml_f="3080" txt_i="206" txt_f="231">forte and 400 mg Migränin</offsets><sup><offsets xml_i="3085" xml_f="3087" txt_i="231" txt_f="233">® </offsets></sup><offsets xml_i="3093" xml_f="3302" txt_i="233" txt_f="442">after single dose administration under fasting conditions in healthy subjects. Therefore the design of a randomized, open label, multiple sequence cross-over study with a wash-out period of 7–10 days was used.</offsets></p></sec><sec><title><offsets xml_i="3324" xml_f="3331" txt_i="444" txt_f="451">Results</offsets></title><p><offsets xml_i="3342" xml_f="3345" txt_i="452" txt_f="455">AUC</offsets><sub><offsets xml_i="3350" xml_f="3360" txt_i="455" txt_f="465">0-t(last) </offsets></sub><offsets xml_i="3366" xml_f="3373" txt_i="465" txt_f="472">and AUC</offsets><sub><offsets xml_i="3378" xml_f="3382" txt_i="472" txt_f="476">0-∞ </offsets></sub><offsets xml_i="3388" xml_f="3515" txt_i="476" txt_f="603">(90%CI) were within the 80 to 125% interval required for bioequivalence as stipulated in the current regulations of the EMEA. C</offsets><sub><offsets xml_i="3520" xml_f="3524" txt_i="603" txt_f="607">max </offsets></sub><offsets xml_i="3530" xml_f="3621" txt_i="607" txt_f="698">(90%CI) was within the EMEA acceptance range of 75 to 133%. Detailed analyses showed that C</offsets><sub><offsets xml_i="3626" xml_f="3630" txt_i="698" txt_f="702">max </offsets></sub><offsets xml_i="3636" xml_f="3647" txt_i="702" txt_f="713">of Eudorlin</offsets><sup><offsets xml_i="3652" xml_f="3654" txt_i="713" txt_f="715">® </offsets></sup><offsets xml_i="3660" xml_f="3697" txt_i="715" txt_f="752">extra was higher than that of Nurofen</offsets><sup><offsets xml_i="3702" xml_f="3704" txt_i="752" txt_f="754">® </offsets></sup><offsets xml_i="3710" xml_f="3772" txt_i="754" txt_f="816">forte (36.62 vs. 32.92 μg/ml; p = 0.0014) and that of Migränin</offsets><sup><offsets xml_i="3777" xml_f="3779" txt_i="816" txt_f="818">® </offsets></sup><offsets xml_i="3785" xml_f="3868" txt_i="818" txt_f="898">(35.94 vs. 30.87 μg/ml; p &lt; 0.0001). The time to maximum plasma concentration (t</offsets><sub><offsets xml_i="3873" xml_f="3876" txt_i="898" txt_f="901">max</offsets></sub><offsets xml_i="3882" xml_f="3909" txt_i="901" txt_f="928">) was shorter with Eudorlin</offsets><sup><offsets xml_i="3914" xml_f="3916" txt_i="928" txt_f="930">® </offsets></sup><offsets xml_i="3922" xml_f="4123" txt_i="930" txt_f="1128">extra than with Nurofen forte (1.14 vs. 1.82 h; p &lt; 0.0001) and Migränin (1.13 vs. 1.78 h; p = 0.0031). Only 1 patient experienced an adverse with possible relation to the study drug taking Migränin</offsets><sup><offsets xml_i="4128" xml_f="4129" txt_i="1128" txt_f="1129">®</offsets></sup><offsets xml_i="4135" xml_f="4136" txt_i="1129" txt_f="1130">.</offsets></p></sec><sec><title><offsets xml_i="4158" xml_f="4168" txt_i="1132" txt_f="1142">Conclusion</offsets></title><p><offsets xml_i="4179" xml_f="4208" txt_i="1143" txt_f="1172">It is concluded that Eudorlin</offsets><sup><offsets xml_i="4213" xml_f="4215" txt_i="1172" txt_f="1174">® </offsets></sup><offsets xml_i="4221" xml_f="4285" txt_i="1174" txt_f="1238">extra is bioequivalent to the two reference preparations Nurofen</offsets><sup><offsets xml_i="4290" xml_f="4292" txt_i="1238" txt_f="1240">® </offsets></sup><offsets xml_i="4298" xml_f="4316" txt_i="1240" txt_f="1258">forte and Migränin</offsets><sup><offsets xml_i="4321" xml_f="4323" txt_i="1258" txt_f="1260">® </offsets></sup><offsets xml_i="4329" xml_f="4602" txt_i="1260" txt_f="1533">for both, the extent and the rate of absorption, after single dose administration in healthy volunteers according to the guidance of the EMEA. Within this frame, peak plasma concentrations are however reached earlier and peaks are higher compared to the reference products.</offsets></p><p><offsets xml_i="4609" xml_f="4619" txt_i="1534" txt_f="1544">* Eudorlin</offsets><sup><offsets xml_i="4624" xml_f="4626" txt_i="1544" txt_f="1546">® </offsets></sup><offsets xml_i="4632" xml_f="4691" txt_i="1546" txt_f="1605">extra may have different brand names in different countries</offsets></p></sec></abstract></article-meta></front><body><sec><title><offsets xml_i="4753" xml_f="4763" txt_i="1614" txt_f="1624">Background</offsets></title><p><offsets xml_i="4774" xml_f="5086" txt_i="1625" txt_f="1937">Ibuprofen was developed during the 1950s and 1960s as a 'super aspirin' for the treatment of rheumatoid arthritis which was as effective as current alternatives but safer. First synthesised in December 1961 ibuprofen was found to have a short elimination half-life and exceptional gastrointestinal tolerability [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="5117" xml_f="5118" txt_i="1937" txt_f="1938">1</offsets></xref><offsets xml_i="5125" xml_f="5588" txt_i="1938" txt_f="2401">]. Ibuprofen is mostly used today in the management of mild to moderate pain and inflammation in conditions such as dysmenorrhoea, headache including migraine, postoperative pain, dental pain, musculoskeletal and joint disorders such as ankylosing spondylitis, osteoarthritis, and rheumatoid arthritis. It is also used to reduce fever. The usual oral dose in adults is 400 to 800 mg daily for analgesia and up to 1600 to 2400 mg for its anti-inflammatory action [</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="5619" xml_f="5620" txt_i="2401" txt_f="2402">2</offsets></xref><offsets xml_i="5627" xml_f="5629" txt_i="2402" txt_f="2404">].</offsets></p><p><offsets xml_i="5636" xml_f="6082" txt_i="2405" txt_f="2851">Ibuprofen is absorbed from the gastro-intestinal tract and peak plasma concentrations are reached within about 1 to 2 hours after ingestion. Bioavailability is ≥ 80%. 99% of ibuprofen is bound to plasma proteins, 90% is transformed to 2 inactive metabolites and it has a plasma half-life of about 2 ± 0.5 hours. It is rapidly excreted in the urine mainly as metabolites and their conjugates. About 1% is excreted in urine as unchanged ibuprofen [</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="6113" xml_f="6114" txt_i="2851" txt_f="2852">2</offsets></xref><offsets xml_i="6121" xml_f="6123" txt_i="2852" txt_f="2854">].</offsets></p><p><offsets xml_i="6130" xml_f="6395" txt_i="2855" txt_f="3120">The European Agency for the Evaluation of Medicinal Products (EMEA) requires generic products that enter the marketplace to show bioequivalence to assess the possibility of alternative use between the reference product and an essentially similar medicinal product [</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="6426" xml_f="6427" txt_i="3120" txt_f="3121">3</offsets></xref><offsets xml_i="6434" xml_f="6864" txt_i="3121" txt_f="3551">]. This is done assuming that in the same subject an essentially similar plasma concentration time course will result in essentially similar concentrations at the site of action and thus in an essentially similar effect. Medicinal products authorized and marketed on the basis of a full dossier i.e. including chemical, biological, pharmaceutical, pharmacological-toxicological and clinical data are used as the reference product.</offsets></p><p><offsets xml_i="6871" xml_f="6978" txt_i="3552" txt_f="3659">The present study was designed to investigate the bioavailability and the bioequivalence of 400 mg Eudorlin</offsets><sup><offsets xml_i="6983" xml_f="6985" txt_i="3659" txt_f="3661">® </offsets></sup><offsets xml_i="6991" xml_f="7047" txt_i="3661" txt_f="3717">extra in comparison to two reference products – Migränin</offsets><sup><offsets xml_i="7052" xml_f="7054" txt_i="3717" txt_f="3719">® </offsets></sup><offsets xml_i="7060" xml_f="7071" txt_i="3719" txt_f="3730">and Nurofen</offsets><sup><offsets xml_i="7076" xml_f="7078" txt_i="3730" txt_f="3732">® </offsets></sup><offsets xml_i="7084" xml_f="7193" txt_i="3732" txt_f="3841">forte after single oral administration (fasting conditions) in healthy subjects following the EMEA guidance [</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="7224" xml_f="7225" txt_i="3841" txt_f="3842">3</offsets></xref><offsets xml_i="7232" xml_f="7498" txt_i="3842" txt_f="4108">]. Two reference products were used since different reference formulations were required in different countries. For this purpose the rate and extent of absorption of ibuprofen under fasting conditions after administration of one tablet of the test product (Eudorlin</offsets><sup><offsets xml_i="7503" xml_f="7505" txt_i="4108" txt_f="4110">® </offsets></sup><offsets xml_i="7511" xml_f="7619" txt_i="4110" txt_f="4218">extra) and one tablet of each of the reference products were compared in a three sequence cross-over design.</offsets></p></sec><sec><title><offsets xml_i="7641" xml_f="7648" txt_i="4220" txt_f="4227">Results</offsets></title><sec><title><offsets xml_i="7668" xml_f="7707" txt_i="4228" txt_f="4267">Demography and baseline characteristics</offsets></title><p><offsets xml_i="7718" xml_f="7736" txt_i="4268" txt_f="4286">Between February 3</offsets><sup><offsets xml_i="7741" xml_f="7744" txt_i="4286" txt_f="4289">rd </offsets></sup><offsets xml_i="7750" xml_f="7761" txt_i="4289" txt_f="4300">and March 8</offsets><sup><offsets xml_i="7766" xml_f="7769" txt_i="4300" txt_f="4303">th </offsets></sup><offsets xml_i="7775" xml_f="8201" txt_i="4303" txt_f="4729">2007 86 subjects were screened for eligibility of whom 60 were enrolled, randomized and available for pharmacokinetic and safety analyses. 41 of these were male, 19 female. There were three protocol violations (Per-protocol population n = 57). For the first patient the labelling of two blood samples was missing, the other two patients missed at least one visit with missing information for that particular time point. Table </offsets><xref ref-type="table" rid="T1"><offsets xml_i="8233" xml_f="8234" txt_i="4729" txt_f="4730">1</offsets></xref><offsets xml_i="8241" xml_f="8373" txt_i="4730" txt_f="4862"> displays the patient characteristics of the pharmacokinetic population by treatment sequence. A refers to reference product Nurofen</offsets><sup><offsets xml_i="8378" xml_f="8380" txt_i="4862" txt_f="4864">® </offsets></sup><offsets xml_i="8386" xml_f="8424" txt_i="4864" txt_f="4902">forte, B to reference product Migränin</offsets><sup><offsets xml_i="8429" xml_f="8431" txt_i="4902" txt_f="4904">® </offsets></sup><offsets xml_i="8437" xml_f="8467" txt_i="4904" txt_f="4934">and E to test product Eudorlin</offsets><sup><offsets xml_i="8472" xml_f="8474" txt_i="4934" txt_f="4936">® </offsets></sup><offsets xml_i="8480" xml_f="8486" txt_i="4936" txt_f="4942">extra.</offsets></p><table-wrap position="float" id="T1"><label><offsets xml_i="8534" xml_f="8541" txt_i="4943" txt_f="4950">Table 1</offsets></label><caption><p><offsets xml_i="8561" xml_f="8589" txt_i="4950" txt_f="4978">Demographic data of subjects</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center"><bold><offsets xml_i="8676" xml_f="8685" txt_i="4979" txt_f="4988">Parameter</offsets></bold></td><td align="center"><bold><offsets xml_i="8722" xml_f="8730" txt_i="4989" txt_f="4997">Sequence</offsets></bold></td><td align="center"><bold><offsets xml_i="8767" xml_f="8768" txt_i="4998" txt_f="4999">N</offsets></bold></td><td align="center"><bold><offsets xml_i="8805" xml_f="8809" txt_i="5000" txt_f="5004">Mean</offsets></bold></td><td align="center"><bold><offsets xml_i="8846" xml_f="8848" txt_i="5005" txt_f="5007">SD</offsets></bold></td><td align="center"><bold><offsets xml_i="8885" xml_f="8891" txt_i="5008" txt_f="5014">Median</offsets></bold></td><td align="center"><bold><offsets xml_i="8928" xml_f="8933" txt_i="5015" txt_f="5020">Range</offsets></bold></td></tr></thead><tbody><tr><td align="center"><offsets xml_i="8988" xml_f="8999" txt_i="5021" txt_f="5032">Age (years)</offsets></td><td align="center"><offsets xml_i="9023" xml_f="9025" txt_i="5033" txt_f="5035">BE</offsets></td><td align="center"><offsets xml_i="9049" xml_f="9051" txt_i="5036" txt_f="5038">20</offsets></td><td align="center"><offsets xml_i="9075" xml_f="9079" txt_i="5039" txt_f="5043">23.9</offsets></td><td align="center"><offsets xml_i="9103" xml_f="9107" txt_i="5044" txt_f="5048">3.65</offsets></td><td align="center"><offsets xml_i="9131" xml_f="9135" txt_i="5049" txt_f="5053">23.5</offsets></td><td align="center"><offsets xml_i="9159" xml_f="9165" txt_i="5054" txt_f="5060">20; 35</offsets></td></tr><tr><td></td><td align="center"><offsets xml_i="9207" xml_f="9209" txt_i="5062" txt_f="5064">EA</offsets></td><td align="center"><offsets xml_i="9233" xml_f="9235" txt_i="5065" txt_f="5067">20</offsets></td><td align="center"><offsets xml_i="9259" xml_f="9263" txt_i="5068" txt_f="5072">25.1</offsets></td><td align="center"><offsets xml_i="9287" xml_f="9291" txt_i="5073" txt_f="5077">5.01</offsets></td><td align="center"><offsets xml_i="9315" xml_f="9319" txt_i="5078" txt_f="5082">24.0</offsets></td><td align="center"><offsets xml_i="9343" xml_f="9349" txt_i="5083" txt_f="5089">20; 39</offsets></td></tr><tr><td></td><td align="center"><offsets xml_i="9391" xml_f="9394" txt_i="5091" txt_f="5094">AEB</offsets></td><td align="center"><offsets xml_i="9418" xml_f="9420" txt_i="5095" txt_f="5097">20</offsets></td><td align="center"><offsets xml_i="9444" xml_f="9448" txt_i="5098" txt_f="5102">27.8</offsets></td><td align="center"><offsets xml_i="9472" xml_f="9476" txt_i="5103" txt_f="5107">6.57</offsets></td><td align="center"><offsets xml_i="9500" xml_f="9504" txt_i="5108" txt_f="5112">26.5</offsets></td><td align="center"><offsets xml_i="9528" xml_f="9534" txt_i="5113" txt_f="5119">20; 45</offsets></td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="center"><offsets xml_i="9606" xml_f="9617" txt_i="5121" txt_f="5132">Weight (kg)</offsets></td><td align="center"><offsets xml_i="9641" xml_f="9643" txt_i="5133" txt_f="5135">BE</offsets></td><td align="center"><offsets xml_i="9667" xml_f="9669" txt_i="5136" txt_f="5138">20</offsets></td><td align="center"><offsets xml_i="9693" xml_f="9697" txt_i="5139" txt_f="5143">68.3</offsets></td><td align="center"><offsets xml_i="9721" xml_f="9726" txt_i="5144" txt_f="5149">10.74</offsets></td><td align="center"><offsets xml_i="9750" xml_f="9754" txt_i="5150" txt_f="5154">69.5</offsets></td><td align="center"><offsets xml_i="9778" xml_f="9784" txt_i="5155" txt_f="5161">50; 90</offsets></td></tr><tr><td></td><td align="center"><offsets xml_i="9826" xml_f="9828" txt_i="5163" txt_f="5165">EA</offsets></td><td align="center"><offsets xml_i="9852" xml_f="9854" txt_i="5166" txt_f="5168">20</offsets></td><td align="center"><offsets xml_i="9878" xml_f="9882" txt_i="5169" txt_f="5173">67.7</offsets></td><td align="center"><offsets xml_i="9906" xml_f="9910" txt_i="5174" txt_f="5178">9.54</offsets></td><td align="center"><offsets xml_i="9934" xml_f="9938" txt_i="5179" txt_f="5183">68.5</offsets></td><td align="center"><offsets xml_i="9962" xml_f="9968" txt_i="5184" txt_f="5190">49; 82</offsets></td></tr><tr><td></td><td align="center"><offsets xml_i="10010" xml_f="10013" txt_i="5192" txt_f="5195">AEB</offsets></td><td align="center"><offsets xml_i="10037" xml_f="10039" txt_i="5196" txt_f="5198">20</offsets></td><td align="center"><offsets xml_i="10063" xml_f="10067" txt_i="5199" txt_f="5203">67.9</offsets></td><td align="center"><offsets xml_i="10091" xml_f="10096" txt_i="5204" txt_f="5209">10.48</offsets></td><td align="center"><offsets xml_i="10120" xml_f="10124" txt_i="5210" txt_f="5214">68.0</offsets></td><td align="center"><offsets xml_i="10148" xml_f="10154" txt_i="5215" txt_f="5221">52; 87</offsets></td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="center"><offsets xml_i="10226" xml_f="10235" txt_i="5223" txt_f="5232">BMI (kg/m</offsets><sup><offsets xml_i="10240" xml_f="10241" txt_i="5232" txt_f="5233">2</offsets></sup><offsets xml_i="10247" xml_f="10250" txt_i="5233" txt_f="5236">) *</offsets></td><td align="center"><offsets xml_i="10274" xml_f="10276" txt_i="5237" txt_f="5239">BE</offsets></td><td align="center"><offsets xml_i="10300" xml_f="10302" txt_i="5240" txt_f="5242">20</offsets></td><td align="center"><offsets xml_i="10326" xml_f="10330" txt_i="5243" txt_f="5247">22.8</offsets></td><td align="center"><offsets xml_i="10354" xml_f="10358" txt_i="5248" txt_f="5252">2.40</offsets></td><td align="center"><offsets xml_i="10382" xml_f="10386" txt_i="5253" txt_f="5257">23.0</offsets></td><td align="center"><offsets xml_i="10410" xml_f="10416" txt_i="5258" txt_f="5264">19; 27</offsets></td></tr><tr><td></td><td align="center"><offsets xml_i="10458" xml_f="10460" txt_i="5266" txt_f="5268">EA</offsets></td><td align="center"><offsets xml_i="10484" xml_f="10486" txt_i="5269" txt_f="5271">20</offsets></td><td align="center"><offsets xml_i="10510" xml_f="10514" txt_i="5272" txt_f="5276">22.9</offsets></td><td align="center"><offsets xml_i="10538" xml_f="10542" txt_i="5277" txt_f="5281">2.29</offsets></td><td align="center"><offsets xml_i="10566" xml_f="10570" txt_i="5282" txt_f="5286">23.0</offsets></td><td align="center"><offsets xml_i="10594" xml_f="10600" txt_i="5287" txt_f="5293">19; 27</offsets></td></tr><tr><td></td><td align="center"><offsets xml_i="10642" xml_f="10645" txt_i="5295" txt_f="5298">AEB</offsets></td><td align="center"><offsets xml_i="10669" xml_f="10671" txt_i="5299" txt_f="5301">20</offsets></td><td align="center"><offsets xml_i="10695" xml_f="10699" txt_i="5302" txt_f="5306">22.2</offsets></td><td align="center"><offsets xml_i="10723" xml_f="10727" txt_i="5307" txt_f="5311">2.67</offsets></td><td align="center"><offsets xml_i="10751" xml_f="10755" txt_i="5312" txt_f="5316">22.0</offsets></td><td align="center"><offsets xml_i="10779" xml_f="10785" txt_i="5317" txt_f="5323">19; 27</offsets></td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td></td><td align="center"><bold><offsets xml_i="10983" xml_f="10991" txt_i="5334" txt_f="5342">Sequence</offsets></bold></td><td align="center"><bold><offsets xml_i="11028" xml_f="11029" txt_i="5343" txt_f="5344">N</offsets></bold></td><td align="center"><bold><offsets xml_i="11066" xml_f="11071" txt_i="5345" txt_f="5350">N (♀)</offsets></bold></td><td align="center"><bold><offsets xml_i="11108" xml_f="11113" txt_i="5351" txt_f="5356">% (♀)</offsets></bold></td><td align="center"><bold><offsets xml_i="11150" xml_f="11155" txt_i="5357" txt_f="5362">N (♂)</offsets></bold></td><td align="center"><bold><offsets xml_i="11192" xml_f="11197" txt_i="5363" txt_f="5368">% (♂)</offsets></bold></td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="center"><offsets xml_i="11276" xml_f="11293" txt_i="5370" txt_f="5387">Female gender (%)</offsets></td><td align="center"><offsets xml_i="11317" xml_f="11319" txt_i="5388" txt_f="5390">BE</offsets></td><td align="center"><offsets xml_i="11343" xml_f="11345" txt_i="5391" txt_f="5393">20</offsets></td><td align="center"><offsets xml_i="11369" xml_f="11370" txt_i="5394" txt_f="5395">7</offsets></td><td align="center"><offsets xml_i="11394" xml_f="11398" txt_i="5396" txt_f="5400">35.0</offsets></td><td align="center"><offsets xml_i="11422" xml_f="11424" txt_i="5401" txt_f="5403">13</offsets></td><td align="center"><offsets xml_i="11448" xml_f="11452" txt_i="5404" txt_f="5408">65.0</offsets></td></tr><tr><td></td><td align="center"><offsets xml_i="11494" xml_f="11496" txt_i="5410" txt_f="5412">EA</offsets></td><td align="center"><offsets xml_i="11520" xml_f="11522" txt_i="5413" txt_f="5415">20</offsets></td><td align="center"><offsets xml_i="11546" xml_f="11547" txt_i="5416" txt_f="5417">6</offsets></td><td align="center"><offsets xml_i="11571" xml_f="11575" txt_i="5418" txt_f="5422">30.0</offsets></td><td align="center"><offsets xml_i="11599" xml_f="11601" txt_i="5423" txt_f="5425">14</offsets></td><td align="center"><offsets xml_i="11625" xml_f="11629" txt_i="5426" txt_f="5430">70.0</offsets></td></tr><tr><td></td><td align="center"><offsets xml_i="11671" xml_f="11674" txt_i="5432" txt_f="5435">AEB</offsets></td><td align="center"><offsets xml_i="11698" xml_f="11700" txt_i="5436" txt_f="5438">20</offsets></td><td align="center"><offsets xml_i="11724" xml_f="11725" txt_i="5439" txt_f="5440">6</offsets></td><td align="center"><offsets xml_i="11749" xml_f="11753" txt_i="5441" txt_f="5445">30.0</offsets></td><td align="center"><offsets xml_i="11777" xml_f="11779" txt_i="5446" txt_f="5448">14</offsets></td><td align="center"><offsets xml_i="11803" xml_f="11807" txt_i="5449" txt_f="5453">70.0</offsets></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="11853" xml_f="11980" txt_i="5454" txt_f="5581">Demography and other baseline characteristics by treatment sequence (Pharmacokinetic population; N = 60). "A" refers to Nurofen</offsets><sup><offsets xml_i="11985" xml_f="11987" txt_i="5581" txt_f="5583">® </offsets></sup><offsets xml_i="11993" xml_f="12022" txt_i="5583" txt_f="5612">forte, "B" refers to Migränin</offsets><sup><offsets xml_i="12027" xml_f="12029" txt_i="5612" txt_f="5614">® </offsets></sup><offsets xml_i="12035" xml_f="12061" txt_i="5614" txt_f="5640">and "E" refers to Eudorlin</offsets><sup><offsets xml_i="12066" xml_f="12068" txt_i="5640" txt_f="5642">® </offsets></sup><offsets xml_i="12074" xml_f="12135" txt_i="5642" txt_f="5703">extra. * calculated from measured height (m) and weight (kg).</offsets></p></table-wrap-foot></table-wrap></sec><sec><title><offsets xml_i="12188" xml_f="12207" txt_i="5705" txt_f="5724">Dissolution testing</offsets></title><p><offsets xml_i="12218" xml_f="12273" txt_i="5725" txt_f="5780">Results of dissolution testing are displayed in Figure </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="12303" xml_f="12304" txt_i="5780" txt_f="5781">1</offsets></xref><offsets xml_i="12311" xml_f="12525" txt_i="5781" txt_f="5995">. Testing was performed for the three products using a total of 504 samples for different time points. All samples resulted in values between 0 and a maximum of 104%. Dissolution was particularly fast with Eudorlin</offsets><sup><offsets xml_i="12530" xml_f="12532" txt_i="5995" txt_f="5997">® </offsets></sup><offsets xml_i="12538" xml_f="12667" txt_i="5997" txt_f="6126">extra resulting in 99% released ibuprofen within 5 minutes. About the same dissolution was observed after 45 minutes with Nurofen</offsets><sup><offsets xml_i="12672" xml_f="12674" txt_i="6126" txt_f="6128">® </offsets></sup><offsets xml_i="12680" xml_f="12721" txt_i="6128" txt_f="6169">forte (99%) and 30 minutes using Migränin</offsets><sup><offsets xml_i="12726" xml_f="12728" txt_i="6169" txt_f="6171">® </offsets></sup><offsets xml_i="12734" xml_f="12741" txt_i="6171" txt_f="6178">(100%).</offsets></p><fig position="float" id="F1"><label><offsets xml_i="12782" xml_f="12790" txt_i="6179" txt_f="6187">Figure 1</offsets></label><caption><p><bold><offsets xml_i="12816" xml_f="12846" txt_i="6187" txt_f="6217">Results of dissolution testing</offsets></bold><offsets xml_i="12853" xml_f="12901" txt_i="6217" txt_f="6265">. Dissolution testing of 400 mg tablets Eudorlin</offsets><sup><offsets xml_i="12906" xml_f="12908" txt_i="6265" txt_f="6267">® </offsets></sup><offsets xml_i="12914" xml_f="12968" txt_i="6267" txt_f="6321">Extra (Test formulation, in red) versus 400 mg Nurofen</offsets><sup><offsets xml_i="12973" xml_f="12975" txt_i="6321" txt_f="6323">® </offsets></sup><offsets xml_i="12981" xml_f="13039" txt_i="6323" txt_f="6381">Forte (Reference formulation 1, black) and 400 mg Migränin</offsets><sup><offsets xml_i="13044" xml_f="13046" txt_i="6381" txt_f="6383">® </offsets></sup><offsets xml_i="13052" xml_f="13092" txt_i="6383" txt_f="6423">(Reference formulation 2, broken black).</offsets></p></caption><graphic xlink:href="1471-2210-8-18-1"></graphic></fig></sec><sec><title><offsets xml_i="13179" xml_f="13194" txt_i="6425" txt_f="6440">Pharmacokinetic</offsets></title><p><offsets xml_i="13205" xml_f="13211" txt_i="6441" txt_f="6447">Table </offsets><xref ref-type="table" rid="T2"><offsets xml_i="13243" xml_f="13244" txt_i="6447" txt_f="6448">2</offsets></xref><offsets xml_i="13251" xml_f="13347" txt_i="6448" txt_f="6544"> displays the pharmacokinetic parameters of the pharmacokinetic (PK) population (n = 60). Table </offsets><xref ref-type="table" rid="T3"><offsets xml_i="13379" xml_f="13380" txt_i="6544" txt_f="6545">3</offsets></xref><offsets xml_i="13387" xml_f="13429" txt_i="6545" txt_f="6587"> illustrates the statistical analysis. AUC</offsets><sub><offsets xml_i="13434" xml_f="13444" txt_i="6587" txt_f="6597">0-t(last) </offsets></sub><offsets xml_i="13450" xml_f="13457" txt_i="6597" txt_f="6604">and AUC</offsets><sub><offsets xml_i="13462" xml_f="13466" txt_i="6604" txt_f="6608">0-∞ </offsets></sub><offsets xml_i="13472" xml_f="13514" txt_i="6608" txt_f="6650">was similar for the comparison of Eudorlin</offsets><sup><offsets xml_i="13519" xml_f="13521" txt_i="6650" txt_f="6652">® </offsets></sup><offsets xml_i="13527" xml_f="13545" txt_i="6652" txt_f="6670">extra with Nurofen</offsets><sup><offsets xml_i="13550" xml_f="13552" txt_i="6670" txt_f="6672">® </offsets></sup><offsets xml_i="13558" xml_f="13576" txt_i="6672" txt_f="6690">forte and Eudorlin</offsets><sup><offsets xml_i="13581" xml_f="13583" txt_i="6690" txt_f="6692">® </offsets></sup><offsets xml_i="13589" xml_f="13608" txt_i="6692" txt_f="6711">extra with Migränin</offsets><sup><offsets xml_i="13613" xml_f="13614" txt_i="6711" txt_f="6712">®</offsets></sup><offsets xml_i="13620" xml_f="13672" txt_i="6712" txt_f="6764">. All estimates of the ratios for the parameters AUC</offsets><sub><offsets xml_i="13677" xml_f="13687" txt_i="6764" txt_f="6774">0-t(last) </offsets></sub><offsets xml_i="13693" xml_f="13700" txt_i="6774" txt_f="6781">and AUC</offsets><sub><offsets xml_i="13705" xml_f="13709" txt_i="6781" txt_f="6785">0-∞ </offsets></sub><offsets xml_i="13715" xml_f="13834" txt_i="6785" txt_f="6904">were near to 1.00 and the 90%-confidence intervals for all comparisons were within the acceptance range of 0.80 – 1.25.</offsets></p><table-wrap position="float" id="T2"><label><offsets xml_i="13882" xml_f="13889" txt_i="6905" txt_f="6912">Table 2</offsets></label><caption><p><offsets xml_i="13909" xml_f="13935" txt_i="6912" txt_f="6938">Pharmacokinetic parameters</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold><offsets xml_i="14020" xml_f="14038" txt_i="6939" txt_f="6957">Parameter analyzed</offsets></bold></td><td align="center"><bold><offsets xml_i="14075" xml_f="14083" txt_i="6958" txt_f="6966">Sequence</offsets></bold></td><td align="left"><bold><offsets xml_i="14118" xml_f="14127" txt_i="6967" txt_f="6976">Treatment</offsets></bold></td><td align="center"><bold><offsets xml_i="14164" xml_f="14168" txt_i="6977" txt_f="6981">Mean</offsets></bold></td><td align="center"><bold><offsets xml_i="14205" xml_f="14207" txt_i="6982" txt_f="6984">SD</offsets></bold></td><td align="center"><bold><offsets xml_i="14244" xml_f="14250" txt_i="6985" txt_f="6991">CV (%)</offsets></bold></td><td align="center"><bold><offsets xml_i="14287" xml_f="14301" txt_i="6992" txt_f="7006">Geometric mean</offsets></bold></td></tr></thead><tbody><tr><td align="left"><offsets xml_i="14354" xml_f="14357" txt_i="7007" txt_f="7010">AUC</offsets><sub><offsets xml_i="14362" xml_f="14372" txt_i="7010" txt_f="7020">0-t(last) </offsets></sub><offsets xml_i="14378" xml_f="14387" txt_i="7020" txt_f="7029">(μg/ml*h)</offsets></td><td align="center"><offsets xml_i="14411" xml_f="14416" txt_i="7030" txt_f="7035">AE/EA</offsets></td><td align="left"><offsets xml_i="14438" xml_f="14445" txt_i="7036" txt_f="7043">Nurofen</offsets><sup><offsets xml_i="14450" xml_f="14451" txt_i="7043" txt_f="7044">®</offsets></sup></td><td align="center"><offsets xml_i="14481" xml_f="14487" txt_i="7045" txt_f="7051">117.00</offsets></td><td align="center"><offsets xml_i="14511" xml_f="14516" txt_i="7052" txt_f="7057">31.94</offsets></td><td align="center"><offsets xml_i="14540" xml_f="14544" txt_i="7058" txt_f="7062">27.3</offsets></td><td align="center"><offsets xml_i="14568" xml_f="14573" txt_i="7063" txt_f="7068">113.4</offsets></td></tr><tr><td></td><td></td><td align="left"><offsets xml_i="14622" xml_f="14630" txt_i="7071" txt_f="7079">Eudorlin</offsets><sup><offsets xml_i="14635" xml_f="14636" txt_i="7079" txt_f="7080">®</offsets></sup></td><td align="center"><offsets xml_i="14666" xml_f="14672" txt_i="7081" txt_f="7087">119.79</offsets></td><td align="center"><offsets xml_i="14696" xml_f="14701" txt_i="7088" txt_f="7093">29.04</offsets></td><td align="center"><offsets xml_i="14725" xml_f="14729" txt_i="7094" txt_f="7098">24.2</offsets></td><td align="center"><offsets xml_i="14753" xml_f="14758" txt_i="7099" txt_f="7104">116.6</offsets></td></tr><tr><td></td><td align="center"><offsets xml_i="14800" xml_f="14805" txt_i="7106" txt_f="7111">EB/BE</offsets></td><td align="left"><offsets xml_i="14827" xml_f="14835" txt_i="7112" txt_f="7120">Migränin</offsets><sup><offsets xml_i="14840" xml_f="14841" txt_i="7120" txt_f="7121">®</offsets></sup></td><td align="center"><offsets xml_i="14871" xml_f="14877" txt_i="7122" txt_f="7128">115.21</offsets></td><td align="center"><offsets xml_i="14901" xml_f="14906" txt_i="7129" txt_f="7134">21.83</offsets></td><td align="center"><offsets xml_i="14930" xml_f="14934" txt_i="7135" txt_f="7139">19.0</offsets></td><td align="center"><offsets xml_i="14958" xml_f="14963" txt_i="7140" txt_f="7145">113.1</offsets></td></tr><tr><td></td><td></td><td align="left"><offsets xml_i="15012" xml_f="15020" txt_i="7148" txt_f="7156">Eudorlin</offsets><sup><offsets xml_i="15025" xml_f="15026" txt_i="7156" txt_f="7157">®</offsets></sup></td><td align="center"><offsets xml_i="15056" xml_f="15062" txt_i="7158" txt_f="7164">115.84</offsets></td><td align="center"><offsets xml_i="15086" xml_f="15091" txt_i="7165" txt_f="7170">22.73</offsets></td><td align="center"><offsets xml_i="15115" xml_f="15119" txt_i="7171" txt_f="7175">19.6</offsets></td><td align="center"><offsets xml_i="15143" xml_f="15148" txt_i="7176" txt_f="7181">113.7</offsets></td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="left"><offsets xml_i="15218" xml_f="15221" txt_i="7183" txt_f="7186">AUC</offsets><sub><offsets xml_i="15226" xml_f="15230" txt_i="7186" txt_f="7190">0-∞ </offsets></sub><offsets xml_i="15236" xml_f="15245" txt_i="7190" txt_f="7199">(μg/ml*h)</offsets></td><td align="center"><offsets xml_i="15269" xml_f="15274" txt_i="7200" txt_f="7205">AE/EA</offsets></td><td align="left"><offsets xml_i="15296" xml_f="15303" txt_i="7206" txt_f="7213">Nurofen</offsets><sup><offsets xml_i="15308" xml_f="15309" txt_i="7213" txt_f="7214">®</offsets></sup></td><td align="center"><offsets xml_i="15339" xml_f="15345" txt_i="7215" txt_f="7221">117.38</offsets></td><td align="center"><offsets xml_i="15369" xml_f="15374" txt_i="7222" txt_f="7227">32.01</offsets></td><td align="center"><offsets xml_i="15398" xml_f="15402" txt_i="7228" txt_f="7232">27.3</offsets></td><td align="center"><offsets xml_i="15426" xml_f="15431" txt_i="7233" txt_f="7238">113.8</offsets></td></tr><tr><td></td><td></td><td align="left"><offsets xml_i="15480" xml_f="15488" txt_i="7241" txt_f="7249">Eudorlin</offsets><sup><offsets xml_i="15493" xml_f="15494" txt_i="7249" txt_f="7250">®</offsets></sup></td><td align="center"><offsets xml_i="15524" xml_f="15530" txt_i="7251" txt_f="7257">120.15</offsets></td><td align="center"><offsets xml_i="15554" xml_f="15559" txt_i="7258" txt_f="7263">29.07</offsets></td><td align="center"><offsets xml_i="15583" xml_f="15587" txt_i="7264" txt_f="7268">24.2</offsets></td><td align="center"><offsets xml_i="15611" xml_f="15616" txt_i="7269" txt_f="7274">117.0</offsets></td></tr><tr><td></td><td align="center"><offsets xml_i="15658" xml_f="15663" txt_i="7276" txt_f="7281">EB/BE</offsets></td><td align="left"><offsets xml_i="15685" xml_f="15693" txt_i="7282" txt_f="7290">Migränin</offsets><sup><offsets xml_i="15698" xml_f="15699" txt_i="7290" txt_f="7291">®</offsets></sup></td><td align="center"><offsets xml_i="15729" xml_f="15735" txt_i="7292" txt_f="7298">115.57</offsets></td><td align="center"><offsets xml_i="15759" xml_f="15764" txt_i="7299" txt_f="7304">21.84</offsets></td><td align="center"><offsets xml_i="15788" xml_f="15792" txt_i="7305" txt_f="7309">18.9</offsets></td><td align="center"><offsets xml_i="15816" xml_f="15821" txt_i="7310" txt_f="7315">113.5</offsets></td></tr><tr><td></td><td></td><td align="left"><offsets xml_i="15870" xml_f="15878" txt_i="7318" txt_f="7326">Eudorlin</offsets><sup><offsets xml_i="15883" xml_f="15884" txt_i="7326" txt_f="7327">®</offsets></sup></td><td align="center"><offsets xml_i="15914" xml_f="15920" txt_i="7328" txt_f="7334">116.22</offsets></td><td align="center"><offsets xml_i="15944" xml_f="15949" txt_i="7335" txt_f="7340">22.73</offsets></td><td align="center"><offsets xml_i="15973" xml_f="15977" txt_i="7341" txt_f="7345">19.6</offsets></td><td align="center"><offsets xml_i="16001" xml_f="16006" txt_i="7346" txt_f="7351">114.1</offsets></td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="left"><offsets xml_i="16076" xml_f="16077" txt_i="7353" txt_f="7354">C</offsets><sub><offsets xml_i="16082" xml_f="16086" txt_i="7354" txt_f="7358">max </offsets></sub><offsets xml_i="16092" xml_f="16099" txt_i="7358" txt_f="7365">(μg/ml)</offsets></td><td align="center"><offsets xml_i="16123" xml_f="16128" txt_i="7366" txt_f="7371">AE/EA</offsets></td><td align="left"><offsets xml_i="16150" xml_f="16157" txt_i="7372" txt_f="7379">Nurofen</offsets><sup><offsets xml_i="16162" xml_f="16163" txt_i="7379" txt_f="7380">®</offsets></sup></td><td align="center"><offsets xml_i="16193" xml_f="16198" txt_i="7381" txt_f="7386">32.92</offsets></td><td align="center"><offsets xml_i="16222" xml_f="16226" txt_i="7387" txt_f="7391">8.29</offsets></td><td align="center"><offsets xml_i="16250" xml_f="16254" txt_i="7392" txt_f="7396">25.2</offsets></td><td align="center"><offsets xml_i="16278" xml_f="16283" txt_i="7397" txt_f="7402">31.83</offsets></td></tr><tr><td></td><td></td><td align="left"><offsets xml_i="16332" xml_f="16340" txt_i="7405" txt_f="7413">Eudorlin</offsets><sup><offsets xml_i="16345" xml_f="16346" txt_i="7413" txt_f="7414">®</offsets></sup></td><td align="center"><offsets xml_i="16376" xml_f="16381" txt_i="7415" txt_f="7420">36.62</offsets></td><td align="center"><offsets xml_i="16405" xml_f="16409" txt_i="7421" txt_f="7425">6.16</offsets></td><td align="center"><offsets xml_i="16433" xml_f="16437" txt_i="7426" txt_f="7430">16.8</offsets></td><td align="center"><offsets xml_i="16461" xml_f="16466" txt_i="7431" txt_f="7436">36.11</offsets></td></tr><tr><td></td><td align="center"><offsets xml_i="16508" xml_f="16513" txt_i="7438" txt_f="7443">EB/BE</offsets></td><td align="left"><offsets xml_i="16535" xml_f="16543" txt_i="7444" txt_f="7452">Migränin</offsets><sup><offsets xml_i="16548" xml_f="16549" txt_i="7452" txt_f="7453">®</offsets></sup></td><td align="center"><offsets xml_i="16579" xml_f="16584" txt_i="7454" txt_f="7459">30.87</offsets></td><td align="center"><offsets xml_i="16608" xml_f="16612" txt_i="7460" txt_f="7464">6.31</offsets></td><td align="center"><offsets xml_i="16636" xml_f="16640" txt_i="7465" txt_f="7469">20.4</offsets></td><td align="center"><offsets xml_i="16664" xml_f="16669" txt_i="7470" txt_f="7475">30.25</offsets></td></tr><tr><td></td><td></td><td align="left"><offsets xml_i="16718" xml_f="16726" txt_i="7478" txt_f="7486">Eudorlin</offsets><sup><offsets xml_i="16731" xml_f="16732" txt_i="7486" txt_f="7487">®</offsets></sup></td><td align="center"><offsets xml_i="16762" xml_f="16767" txt_i="7488" txt_f="7493">35.94</offsets></td><td align="center"><offsets xml_i="16791" xml_f="16795" txt_i="7494" txt_f="7498">6.30</offsets></td><td align="center"><offsets xml_i="16819" xml_f="16823" txt_i="7499" txt_f="7503">17.5</offsets></td><td align="center"><offsets xml_i="16847" xml_f="16852" txt_i="7504" txt_f="7509">35.41</offsets></td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="left"><offsets xml_i="16922" xml_f="16923" txt_i="7511" txt_f="7512">t</offsets><sub><offsets xml_i="16928" xml_f="16932" txt_i="7512" txt_f="7516">1/2 </offsets></sub><offsets xml_i="16938" xml_f="16941" txt_i="7516" txt_f="7519">(h)</offsets></td><td align="center"><offsets xml_i="16965" xml_f="16970" txt_i="7520" txt_f="7525">AE/EA</offsets></td><td align="left"><offsets xml_i="16992" xml_f="16999" txt_i="7526" txt_f="7533">Nurofen</offsets><sup><offsets xml_i="17004" xml_f="17005" txt_i="7533" txt_f="7534">®</offsets></sup></td><td align="center"><offsets xml_i="17035" xml_f="17039" txt_i="7535" txt_f="7539">2.52</offsets></td><td align="center"><offsets xml_i="17063" xml_f="17067" txt_i="7540" txt_f="7544">0.44</offsets></td><td align="center"><offsets xml_i="17091" xml_f="17095" txt_i="7545" txt_f="7549">17.6</offsets></td><td align="center"><offsets xml_i="17119" xml_f="17124" txt_i="7550" txt_f="7555">2.495</offsets></td></tr><tr><td></td><td></td><td align="left"><offsets xml_i="17173" xml_f="17181" txt_i="7558" txt_f="7566">Eudorlin</offsets><sup><offsets xml_i="17186" xml_f="17187" txt_i="7566" txt_f="7567">®</offsets></sup></td><td align="center"><offsets xml_i="17217" xml_f="17221" txt_i="7568" txt_f="7572">2.55</offsets></td><td align="center"><offsets xml_i="17245" xml_f="17249" txt_i="7573" txt_f="7577">0.42</offsets></td><td align="center"><offsets xml_i="17273" xml_f="17277" txt_i="7578" txt_f="7582">16.6</offsets></td><td align="center"><offsets xml_i="17301" xml_f="17306" txt_i="7583" txt_f="7588">2.522</offsets></td></tr><tr><td></td><td align="center"><offsets xml_i="17348" xml_f="17353" txt_i="7590" txt_f="7595">EB/BE</offsets></td><td align="left"><offsets xml_i="17375" xml_f="17383" txt_i="7596" txt_f="7604">Migränin</offsets><sup><offsets xml_i="17388" xml_f="17389" txt_i="7604" txt_f="7605">®</offsets></sup></td><td align="center"><offsets xml_i="17419" xml_f="17423" txt_i="7606" txt_f="7610">2.50</offsets></td><td align="center"><offsets xml_i="17447" xml_f="17451" txt_i="7611" txt_f="7615">0.33</offsets></td><td align="center"><offsets xml_i="17475" xml_f="17479" txt_i="7616" txt_f="7620">13.1</offsets></td><td align="center"><offsets xml_i="17503" xml_f="17508" txt_i="7621" txt_f="7626">2.478</offsets></td></tr><tr><td></td><td></td><td align="left"><offsets xml_i="17557" xml_f="17565" txt_i="7629" txt_f="7637">Eudorlin</offsets><sup><offsets xml_i="17570" xml_f="17571" txt_i="7637" txt_f="7638">®</offsets></sup></td><td align="center"><offsets xml_i="17601" xml_f="17605" txt_i="7639" txt_f="7643">2.66</offsets></td><td align="center"><offsets xml_i="17629" xml_f="17633" txt_i="7644" txt_f="7648">0.79</offsets></td><td align="center"><offsets xml_i="17657" xml_f="17661" txt_i="7649" txt_f="7653">29.8</offsets></td><td align="center"><offsets xml_i="17685" xml_f="17690" txt_i="7654" txt_f="7659">2.583</offsets></td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td></td><td></td><td></td><td align="center"><bold><offsets xml_i="17906" xml_f="17910" txt_i="7672" txt_f="7676">Mean</offsets></bold></td><td align="center"><bold><offsets xml_i="17947" xml_f="17949" txt_i="7677" txt_f="7679">SD</offsets></bold></td><td align="center"><bold><offsets xml_i="17986" xml_f="17988" txt_i="7680" txt_f="7682">CV</offsets></bold></td><td align="center"><bold><offsets xml_i="18025" xml_f="18031" txt_i="7683" txt_f="7689">Median</offsets></bold></td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="left"><offsets xml_i="18108" xml_f="18109" txt_i="7691" txt_f="7692">t</offsets><sub><offsets xml_i="18114" xml_f="18118" txt_i="7692" txt_f="7696">max </offsets></sub><offsets xml_i="18124" xml_f="18127" txt_i="7696" txt_f="7699">(h)</offsets></td><td align="center"><offsets xml_i="18151" xml_f="18156" txt_i="7700" txt_f="7705">AE/EA</offsets></td><td align="left"><offsets xml_i="18178" xml_f="18185" txt_i="7706" txt_f="7713">Nurofen</offsets><sup><offsets xml_i="18190" xml_f="18191" txt_i="7713" txt_f="7714">®</offsets></sup></td><td align="center"><offsets xml_i="18221" xml_f="18225" txt_i="7715" txt_f="7719">1.82</offsets></td><td align="center"><offsets xml_i="18249" xml_f="18253" txt_i="7720" txt_f="7724">1.05</offsets></td><td align="center"><offsets xml_i="18277" xml_f="18281" txt_i="7725" txt_f="7729">57.9</offsets></td><td align="center"><offsets xml_i="18305" xml_f="18309" txt_i="7730" txt_f="7734">1.50</offsets></td></tr><tr><td></td><td></td><td align="left"><offsets xml_i="18358" xml_f="18366" txt_i="7737" txt_f="7745">Eudorlin</offsets><sup><offsets xml_i="18371" xml_f="18372" txt_i="7745" txt_f="7746">®</offsets></sup></td><td align="center"><offsets xml_i="18402" xml_f="18406" txt_i="7747" txt_f="7751">1.14</offsets></td><td align="center"><offsets xml_i="18430" xml_f="18434" txt_i="7752" txt_f="7756">0.67</offsets></td><td align="center"><offsets xml_i="18458" xml_f="18462" txt_i="7757" txt_f="7761">59.1</offsets></td><td align="center"><offsets xml_i="18486" xml_f="18490" txt_i="7762" txt_f="7766">1.00</offsets></td></tr><tr><td></td><td align="center"><offsets xml_i="18532" xml_f="18537" txt_i="7768" txt_f="7773">EB/BE</offsets></td><td align="left"><offsets xml_i="18559" xml_f="18567" txt_i="7774" txt_f="7782">Migränin</offsets><sup><offsets xml_i="18572" xml_f="18573" txt_i="7782" txt_f="7783">®</offsets></sup></td><td align="center"><offsets xml_i="18603" xml_f="18607" txt_i="7784" txt_f="7788">1.78</offsets></td><td align="center"><offsets xml_i="18631" xml_f="18635" txt_i="7789" txt_f="7793">0.97</offsets></td><td align="center"><offsets xml_i="18659" xml_f="18663" txt_i="7794" txt_f="7798">54.5</offsets></td><td align="center"><offsets xml_i="18687" xml_f="18691" txt_i="7799" txt_f="7803">1.75</offsets></td></tr><tr><td></td><td></td><td align="left"><offsets xml_i="18740" xml_f="18748" txt_i="7806" txt_f="7814">Eudorlin</offsets><sup><offsets xml_i="18753" xml_f="18754" txt_i="7814" txt_f="7815">®</offsets></sup></td><td align="center"><offsets xml_i="18784" xml_f="18788" txt_i="7816" txt_f="7820">1.13</offsets></td><td align="center"><offsets xml_i="18812" xml_f="18816" txt_i="7821" txt_f="7825">0.80</offsets></td><td align="center"><offsets xml_i="18840" xml_f="18844" txt_i="7826" txt_f="7830">71.1</offsets></td><td align="center"><offsets xml_i="18868" xml_f="18872" txt_i="7831" txt_f="7835">0.75</offsets></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="18918" xml_f="19030" txt_i="7836" txt_f="7948">Pharmacokinetic data by treatment pair and treatment (Pharmacokinetic population; N = 60). "A" refers to Nurofen</offsets><sup><offsets xml_i="19035" xml_f="19037" txt_i="7948" txt_f="7950">® </offsets></sup><offsets xml_i="19043" xml_f="19072" txt_i="7950" txt_f="7979">forte, "B" refers to Migränin</offsets><sup><offsets xml_i="19077" xml_f="19079" txt_i="7979" txt_f="7981">® </offsets></sup><offsets xml_i="19085" xml_f="19111" txt_i="7981" txt_f="8007">and "E" refers to Eudorlin</offsets><sup><offsets xml_i="19116" xml_f="19118" txt_i="8007" txt_f="8009">® </offsets></sup><offsets xml_i="19124" xml_f="19184" txt_i="8009" txt_f="8069">extra. SD: standard deviation, CV: coefficient of variation.</offsets></p></table-wrap-foot></table-wrap><table-wrap position="float" id="T3"><label><offsets xml_i="19263" xml_f="19270" txt_i="8070" txt_f="8077">Table 3</offsets></label><caption><p><offsets xml_i="19290" xml_f="19318" txt_i="8077" txt_f="8105">Statistical analysis for AUC</offsets><sub><offsets xml_i="19323" xml_f="19332" txt_i="8105" txt_f="8114">0-t(last)</offsets></sub><offsets xml_i="19338" xml_f="19343" txt_i="8114" txt_f="8119">, AUC</offsets><sub><offsets xml_i="19348" xml_f="19352" txt_i="8119" txt_f="8123">0-∞ </offsets></sub><offsets xml_i="19358" xml_f="19363" txt_i="8123" txt_f="8128">and C</offsets><sub><offsets xml_i="19368" xml_f="19371" txt_i="8128" txt_f="8131">max</offsets></sub></p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold><offsets xml_i="19462" xml_f="19471" txt_i="8132" txt_f="8141">Parameter</offsets></bold></td><td align="center"><bold><offsets xml_i="19508" xml_f="19513" txt_i="8142" txt_f="8147">Ratio</offsets></bold></td><td align="center"><bold><offsets xml_i="19550" xml_f="19558" txt_i="8148" txt_f="8156">Estimate</offsets></bold></td><td align="center"><bold><offsets xml_i="19595" xml_f="19600" txt_i="8157" txt_f="8162">90%CI</offsets></bold></td></tr></thead><tbody><tr><td align="left"><offsets xml_i="19653" xml_f="19656" txt_i="8163" txt_f="8166">AUC</offsets><sub><offsets xml_i="19661" xml_f="19670" txt_i="8166" txt_f="8175">0-t(last)</offsets></sub></td><td align="center"><offsets xml_i="19700" xml_f="19703" txt_i="8176" txt_f="8179">E/A</offsets></td><td align="center"><offsets xml_i="19727" xml_f="19733" txt_i="8180" txt_f="8186">1.0241</offsets></td><td align="center"><offsets xml_i="19757" xml_f="19771" txt_i="8187" txt_f="8201">0.9959; 1.0531</offsets></td></tr><tr><td></td><td align="center"><offsets xml_i="19813" xml_f="19816" txt_i="8203" txt_f="8206">E/B</offsets></td><td align="center"><offsets xml_i="19840" xml_f="19846" txt_i="8207" txt_f="8213">1.0058</offsets></td><td align="center"><offsets xml_i="19870" xml_f="19884" txt_i="8214" txt_f="8228">0.9700; 1.0430</offsets></td></tr><tr><td align="left"><offsets xml_i="19915" xml_f="19918" txt_i="8229" txt_f="8232">AUC</offsets><sub><offsets xml_i="19923" xml_f="19926" txt_i="8232" txt_f="8235">0-∞</offsets></sub></td><td align="center"><offsets xml_i="19956" xml_f="19959" txt_i="8236" txt_f="8239">E/A</offsets></td><td align="center"><offsets xml_i="19983" xml_f="19989" txt_i="8240" txt_f="8246">1.0240</offsets></td><td align="center"><offsets xml_i="20013" xml_f="20027" txt_i="8247" txt_f="8261">0.9958; 1.0529</offsets></td></tr><tr><td></td><td align="center"><offsets xml_i="20069" xml_f="20072" txt_i="8263" txt_f="8266">E/B</offsets></td><td align="center"><offsets xml_i="20096" xml_f="20102" txt_i="8267" txt_f="8273">1.0060</offsets></td><td align="center"><offsets xml_i="20126" xml_f="20140" txt_i="8274" txt_f="8288">0.9704; 1.0430</offsets></td></tr><tr><td align="left"><offsets xml_i="20171" xml_f="20172" txt_i="8289" txt_f="8290">C</offsets><sub><offsets xml_i="20177" xml_f="20180" txt_i="8290" txt_f="8293">max</offsets></sub></td><td align="center"><offsets xml_i="20210" xml_f="20213" txt_i="8294" txt_f="8297">E/A</offsets></td><td align="center"><offsets xml_i="20237" xml_f="20243" txt_i="8298" txt_f="8304">1.1084</offsets></td><td align="center"><offsets xml_i="20267" xml_f="20281" txt_i="8305" txt_f="8319">1.0542; 1.1852</offsets></td></tr><tr><td></td><td align="center"><offsets xml_i="20323" xml_f="20326" txt_i="8321" txt_f="8324">E/B</offsets></td><td align="center"><offsets xml_i="20350" xml_f="20356" txt_i="8325" txt_f="8331">1.1732</offsets></td><td align="center"><offsets xml_i="20380" xml_f="20394" txt_i="8332" txt_f="8346">1.1058; 1.2447</offsets></td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td></td><td></td><td></td><td></td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left"><bold><offsets xml_i="20554" xml_f="20563" txt_i="8353" txt_f="8362">Parameter</offsets></bold></td><td align="center"><bold><offsets xml_i="20600" xml_f="20610" txt_i="8363" txt_f="8373">Difference</offsets></bold></td><td align="center"><bold><offsets xml_i="20647" xml_f="20655" txt_i="8374" txt_f="8382">Estimate</offsets></bold></td><td align="center"><bold><offsets xml_i="20692" xml_f="20697" txt_i="8383" txt_f="8388">90%CI</offsets></bold></td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left"><offsets xml_i="20774" xml_f="20775" txt_i="8390" txt_f="8391">t</offsets><sub><offsets xml_i="20780" xml_f="20783" txt_i="8391" txt_f="8394">max</offsets></sub></td><td align="center"><offsets xml_i="20813" xml_f="20818" txt_i="8395" txt_f="8400">E – A</offsets></td><td align="center"><offsets xml_i="20842" xml_f="20849" txt_i="8401" txt_f="8408">-0.6250</offsets></td><td align="center"><offsets xml_i="20873" xml_f="20889" txt_i="8409" txt_f="8425">-0.8750; -0.3750</offsets></td></tr><tr><td></td><td align="center"><offsets xml_i="20931" xml_f="20936" txt_i="8427" txt_f="8432">E – B</offsets></td><td align="center"><offsets xml_i="20960" xml_f="20967" txt_i="8433" txt_f="8440">-0.6875</offsets></td><td align="center"><offsets xml_i="20991" xml_f="21006" txt_i="8441" txt_f="8456">-1.000; -0.3750</offsets></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="21052" xml_f="21171" txt_i="8457" txt_f="8576">Statistical analysis by treatment pair (parametric analysis, pharmacokinetic population; N = 60). "A" refers to Nurofen</offsets><sup><offsets xml_i="21176" xml_f="21178" txt_i="8576" txt_f="8578">® </offsets></sup><offsets xml_i="21184" xml_f="21213" txt_i="8578" txt_f="8607">forte, "B" refers to Migränin</offsets><sup><offsets xml_i="21218" xml_f="21220" txt_i="8607" txt_f="8609">® </offsets></sup><offsets xml_i="21226" xml_f="21252" txt_i="8609" txt_f="8635">and "E" refers to Eudorlin</offsets><sup><offsets xml_i="21257" xml_f="21259" txt_i="8635" txt_f="8637">® </offsets></sup><offsets xml_i="21265" xml_f="21296" txt_i="8637" txt_f="8668">extra. CI: confidence interval.</offsets></p></table-wrap-foot></table-wrap><p><offsets xml_i="21334" xml_f="21344" txt_i="8669" txt_f="8679">The mean C</offsets><sub><offsets xml_i="21349" xml_f="21353" txt_i="8679" txt_f="8683">max </offsets></sub><offsets xml_i="21359" xml_f="21395" txt_i="8683" txt_f="8719">of ibuprofen differed after Eudorlin</offsets><sup><offsets xml_i="21400" xml_f="21402" txt_i="8719" txt_f="8721">® </offsets></sup><offsets xml_i="21408" xml_f="21433" txt_i="8721" txt_f="8746">extra compared to Nurofen</offsets><sup><offsets xml_i="21438" xml_f="21440" txt_i="8746" txt_f="8748">® </offsets></sup><offsets xml_i="21446" xml_f="21506" txt_i="8748" txt_f="8808">forte (36.62 vs. 32.92 μg/ml; p = 0.0014) and after Eudorlin</offsets><sup><offsets xml_i="21511" xml_f="21513" txt_i="8808" txt_f="8810">® </offsets></sup><offsets xml_i="21519" xml_f="21545" txt_i="8810" txt_f="8836">extra compared to Migränin</offsets><sup><offsets xml_i="21550" xml_f="21552" txt_i="8836" txt_f="8838">® </offsets></sup><offsets xml_i="21558" xml_f="21788" txt_i="8838" txt_f="9065">(35.94 vs. 30.87 μg/ml; p &lt; 0.0001). The 90%-confidence intervals for both comparisons were however within the widened acceptance range of 0.75 – 1.33 (pre-defined), but also within the standard acceptance range of 0.80 – 1.25.</offsets></p><p><offsets xml_i="21795" xml_f="21800" txt_i="9066" txt_f="9071">The t</offsets><sub><offsets xml_i="21805" xml_f="21809" txt_i="9071" txt_f="9075">max </offsets></sub><offsets xml_i="21815" xml_f="21834" txt_i="9075" txt_f="9094">varied for Eudorlin</offsets><sup><offsets xml_i="21839" xml_f="21841" txt_i="9094" txt_f="9096">® </offsets></sup><offsets xml_i="21847" xml_f="21912" txt_i="9096" txt_f="9161">extra between 0.25 to 3.50 hours and after treatment with Nurofen</offsets><sup><offsets xml_i="21917" xml_f="21919" txt_i="9161" txt_f="9163">® </offsets></sup><offsets xml_i="21925" xml_f="21942" txt_i="9163" txt_f="9180">forte or Migränin</offsets><sup><offsets xml_i="21947" xml_f="21949" txt_i="9180" txt_f="9182">® </offsets></sup><offsets xml_i="21955" xml_f="21990" txt_i="9182" txt_f="9217">between 0.50 and 5.00 hours (Table </offsets><xref ref-type="table" rid="T2"><offsets xml_i="22022" xml_f="22023" txt_i="9217" txt_f="9218">2</offsets></xref><offsets xml_i="22030" xml_f="22098" txt_i="9218" txt_f="9286"> displays the mean values ± standard deviation). The difference in t</offsets><sub><offsets xml_i="22103" xml_f="22107" txt_i="9286" txt_f="9290">max </offsets></sub><offsets xml_i="22113" xml_f="22124" txt_i="9290" txt_f="9301">of Eudorlin</offsets><sup><offsets xml_i="22129" xml_f="22131" txt_i="9301" txt_f="9303">® </offsets></sup><offsets xml_i="22137" xml_f="22154" txt_i="9303" txt_f="9320">extra and Nurofen</offsets><sup><offsets xml_i="22159" xml_f="22161" txt_i="9320" txt_f="9322">® </offsets></sup><offsets xml_i="22167" xml_f="22268" txt_i="9322" txt_f="9420">was statistically significant (1.14 vs. 1.82 h; p &lt; 0.0001) as was the difference between Eudorlin</offsets><sup><offsets xml_i="22273" xml_f="22275" txt_i="9420" txt_f="9422">® </offsets></sup><offsets xml_i="22281" xml_f="22299" txt_i="9422" txt_f="9440">extra and Migränin</offsets><sup><offsets xml_i="22304" xml_f="22306" txt_i="9440" txt_f="9442">® </offsets></sup><offsets xml_i="22312" xml_f="22340" txt_i="9442" txt_f="9470">(1.13 vs. 1.78; p = 0.0031).</offsets></p><p><offsets xml_i="22347" xml_f="22400" txt_i="9471" txt_f="9524">As an additional variable the elimination half life t</offsets><sub><offsets xml_i="22405" xml_f="22409" txt_i="9524" txt_f="9528">1/2 </offsets></sub><offsets xml_i="22415" xml_f="22463" txt_i="9528" txt_f="9576">was calculated. The mean elimination half life t</offsets><sub><offsets xml_i="22468" xml_f="22472" txt_i="9576" txt_f="9580">1/2 </offsets></sub><offsets xml_i="22478" xml_f="22546" txt_i="9580" txt_f="9648">values were similar for all treatments with 2.52 hours after Nurofen</offsets><sup><offsets xml_i="22551" xml_f="22553" txt_i="9648" txt_f="9650">® </offsets></sup><offsets xml_i="22559" xml_f="22591" txt_i="9650" txt_f="9682">forte, 2.50 hours after Migränin</offsets><sup><offsets xml_i="22596" xml_f="22598" txt_i="9682" txt_f="9684">® </offsets></sup><offsets xml_i="22604" xml_f="22638" txt_i="9684" txt_f="9718">and slightly higher after Eudorlin</offsets><sup><offsets xml_i="22643" xml_f="22645" txt_i="9718" txt_f="9720">® </offsets></sup><offsets xml_i="22651" xml_f="22701" txt_i="9720" txt_f="9770">extra with 2.55 or 2.66 hours compared to Migränin</offsets><sup><offsets xml_i="22706" xml_f="22708" txt_i="9770" txt_f="9772">® </offsets></sup><offsets xml_i="22714" xml_f="22724" txt_i="9772" txt_f="9782">or Nurofen</offsets><sup><offsets xml_i="22729" xml_f="22731" txt_i="9782" txt_f="9784">® </offsets></sup><offsets xml_i="22737" xml_f="22756" txt_i="9784" txt_f="9803">forte respectively.</offsets></p><p><offsets xml_i="22763" xml_f="22839" txt_i="9804" txt_f="9880">The graphic geometric mean time curves for plasma concentration for Eudorlin</offsets><sup><offsets xml_i="22844" xml_f="22846" txt_i="9880" txt_f="9882">® </offsets></sup><offsets xml_i="22852" xml_f="22902" txt_i="9882" txt_f="9932">extra compared to the reference products – Nurofen</offsets><sup><offsets xml_i="22907" xml_f="22909" txt_i="9932" txt_f="9934">® </offsets></sup><offsets xml_i="22915" xml_f="22933" txt_i="9934" txt_f="9952">forte and Migränin</offsets><sup><offsets xml_i="22938" xml_f="22940" txt_i="9952" txt_f="9954">® </offsets></sup><offsets xml_i="22946" xml_f="23029" txt_i="9954" txt_f="10037">were similar with a slightly higher and earlier geometric mean maximum for Eudorlin</offsets><sup><offsets xml_i="23034" xml_f="23036" txt_i="10037" txt_f="10039">® </offsets></sup><offsets xml_i="23042" xml_f="23061" txt_i="10039" txt_f="10058">extra (see Figures </offsets><xref ref-type="fig" rid="F2"><offsets xml_i="23091" xml_f="23092" txt_i="10058" txt_f="10059">2</offsets></xref><offsets xml_i="23099" xml_f="23104" txt_i="10059" txt_f="10064"> and </offsets><xref ref-type="fig" rid="F3"><offsets xml_i="23134" xml_f="23135" txt_i="10064" txt_f="10065">3</offsets></xref><offsets xml_i="23142" xml_f="23144" txt_i="10065" txt_f="10067">).</offsets></p><fig position="float" id="F2"><label><offsets xml_i="23185" xml_f="23193" txt_i="10068" txt_f="10076">Figure 2</offsets></label><caption><p><bold><offsets xml_i="23219" xml_f="23259" txt_i="10076" txt_f="10116">Plasma concentration time curve Eudorlin</offsets><sup><offsets xml_i="23264" xml_f="23266" txt_i="10116" txt_f="10118">® </offsets></sup><offsets xml_i="23272" xml_f="23283" txt_i="10118" txt_f="10129">vs. Nurofen</offsets><sup><offsets xml_i="23288" xml_f="23289" txt_i="10129" txt_f="10130">®</offsets></sup></bold><offsets xml_i="23302" xml_f="23388" txt_i="10130" txt_f="10216">. Geometric mean time curve for plasma concentration of ibuprofen; cross-over Eudorlin</offsets><sup><offsets xml_i="23393" xml_f="23395" txt_i="10216" txt_f="10218">® </offsets></sup><offsets xml_i="23401" xml_f="23416" txt_i="10218" txt_f="10233">extra – Nurofen</offsets><sup><offsets xml_i="23421" xml_f="23423" txt_i="10233" txt_f="10235">® </offsets></sup><offsets xml_i="23429" xml_f="23472" txt_i="10235" txt_f="10278">forte (Pharmacokinetic population; N = 60).</offsets></p></caption><graphic xlink:href="1471-2210-8-18-2"></graphic></fig><fig position="float" id="F3"><label><offsets xml_i="23578" xml_f="23586" txt_i="10279" txt_f="10287">Figure 3</offsets></label><caption><p><bold><offsets xml_i="23612" xml_f="23652" txt_i="10287" txt_f="10327">Plasma concentration time curve Eudorlin</offsets><sup><offsets xml_i="23657" xml_f="23659" txt_i="10327" txt_f="10329">® </offsets></sup><offsets xml_i="23665" xml_f="23677" txt_i="10329" txt_f="10341">vs. Migränin</offsets><sup><offsets xml_i="23682" xml_f="23683" txt_i="10341" txt_f="10342">®</offsets></sup></bold><offsets xml_i="23696" xml_f="23782" txt_i="10342" txt_f="10428">. Geometric mean time curve for plasma concentration of ibuprofen; cross-over Eudorlin</offsets><sup><offsets xml_i="23787" xml_f="23789" txt_i="10428" txt_f="10430">® </offsets></sup><offsets xml_i="23795" xml_f="23811" txt_i="10430" txt_f="10446">extra – Migränin</offsets><sup><offsets xml_i="23816" xml_f="23818" txt_i="10446" txt_f="10448">® </offsets></sup><offsets xml_i="23824" xml_f="23861" txt_i="10448" txt_f="10485">(Pharmacokinetic population; N = 60).</offsets></p></caption><graphic xlink:href="1471-2210-8-18-3"></graphic></fig></sec><sec><title><offsets xml_i="23948" xml_f="23954" txt_i="10487" txt_f="10493">Safety</offsets></title><p><offsets xml_i="23965" xml_f="24116" txt_i="10494" txt_f="10645">14 subjects of the safety population (N = 60) reported a total of 20 adverse events during the study, 6 of these subjects after treatment with Eudorlin</offsets><sup><offsets xml_i="24121" xml_f="24123" txt_i="10645" txt_f="10647">® </offsets></sup><offsets xml_i="24129" xml_f="24151" txt_i="10647" txt_f="10669">extra, 6 after Nurofen</offsets><sup><offsets xml_i="24156" xml_f="24158" txt_i="10669" txt_f="10671">® </offsets></sup><offsets xml_i="24164" xml_f="24190" txt_i="10671" txt_f="10697">forte and 4 after Migränin</offsets><sup><offsets xml_i="24195" xml_f="24196" txt_i="10697" txt_f="10698">®</offsets></sup><offsets xml_i="24202" xml_f="24329" txt_i="10698" txt_f="10825">. The only adverse event with a possible relation to the study drug was headache reported by 1 subject after intake of Migränin</offsets><sup><offsets xml_i="24334" xml_f="24335" txt_i="10825" txt_f="10826">®</offsets></sup><offsets xml_i="24341" xml_f="24389" txt_i="10826" txt_f="10874">. 19 were unrelated and 2 unlikely drug related.</offsets></p></sec></sec><sec><title><offsets xml_i="24417" xml_f="24427" txt_i="10877" txt_f="10887">Discussion</offsets></title><p><offsets xml_i="24438" xml_f="24506" txt_i="10888" txt_f="10956">The results of this study demonstrate that a single dose of Eudorlin</offsets><sup><offsets xml_i="24511" xml_f="24513" txt_i="10956" txt_f="10958">® </offsets></sup><offsets xml_i="24519" xml_f="24608" txt_i="10958" txt_f="11047">extra results in similar total systemic exposure (as measured by AUC) compared to Nurofen</offsets><sup><offsets xml_i="24613" xml_f="24615" txt_i="11047" txt_f="11049">® </offsets></sup><offsets xml_i="24621" xml_f="24645" txt_i="11049" txt_f="11073">forte and after Migränin</offsets><sup><offsets xml_i="24650" xml_f="24652" txt_i="11073" txt_f="11075">® </offsets></sup><offsets xml_i="24658" xml_f="24725" txt_i="11075" txt_f="11142">throughout a 24 h period. However, the peak plasma concentration (C</offsets><sub><offsets xml_i="24730" xml_f="24733" txt_i="11142" txt_f="11145">max</offsets></sub><offsets xml_i="24739" xml_f="24796" txt_i="11145" txt_f="11202">) was higher and the time to peak plasma concentration (t</offsets><sub><offsets xml_i="24801" xml_f="24804" txt_i="11202" txt_f="11205">max</offsets></sub><offsets xml_i="24810" xml_f="24957" txt_i="11205" txt_f="11352">) shorter in comparison to the two reference formulations suggesting a more rapid absorption of the test formulation (for illustration see Figures </offsets><xref ref-type="fig" rid="F2"><offsets xml_i="24987" xml_f="24988" txt_i="11352" txt_f="11353">2</offsets></xref><offsets xml_i="24995" xml_f="25000" txt_i="11353" txt_f="11358"> and </offsets><xref ref-type="fig" rid="F3"><offsets xml_i="25030" xml_f="25031" txt_i="11358" txt_f="11359">3</offsets></xref><offsets xml_i="25038" xml_f="25277" txt_i="11359" txt_f="11598">). These results are consistent with the results of the dissolution testing which suggested a faster release of ibuprofen from the test formulation. All measures are however within the acceptance range of the EMEA bioequivalence guidance [</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="25308" xml_f="25309" txt_i="11598" txt_f="11599">3</offsets></xref><offsets xml_i="25316" xml_f="25383" txt_i="11599" txt_f="11666">]. This asks to demonstrate that the 90% confidence interval of AUC</offsets><sub><offsets xml_i="25388" xml_f="25397" txt_i="11666" txt_f="11675">0-t(last)</offsets></sub><offsets xml_i="25403" xml_f="25408" txt_i="11675" txt_f="11680">, AUC</offsets><sub><offsets xml_i="25413" xml_f="25417" txt_i="11680" txt_f="11684">0-∞ </offsets></sub><offsets xml_i="25423" xml_f="25428" txt_i="11684" txt_f="11689">and C</offsets><sub><offsets xml_i="25433" xml_f="25437" txt_i="11689" txt_f="11693">max </offsets></sub><offsets xml_i="25443" xml_f="25494" txt_i="11693" txt_f="11744">lie within an acceptance range of 80 – 125% while t</offsets><sub><offsets xml_i="25499" xml_f="25503" txt_i="11744" txt_f="11748">max </offsets></sub><offsets xml_i="25509" xml_f="25586" txt_i="11748" txt_f="11825">should lie within a clinically determined range but is not further specified.</offsets></p><sec><title><offsets xml_i="25602" xml_f="25647" txt_i="11826" txt_f="11871">Acceptance range peak plasma concentration (C</offsets><sub><offsets xml_i="25652" xml_f="25655" txt_i="11871" txt_f="11874">max</offsets></sub><offsets xml_i="25661" xml_f="25662" txt_i="11874" txt_f="11875">)</offsets></title><p><offsets xml_i="25673" xml_f="25782" txt_i="11876" txt_f="11985">Ibuprofen has shown to have a low acute and chronic toxicity in a number of clinical studies and registries [</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="25813" xml_f="25814" txt_i="11985" txt_f="11986">2</offsets></xref><offsets xml_i="25821" xml_f="25961" txt_i="11986" txt_f="12126">], in particular using the low dose tested. An evaluation of reported side effects after single doses in 15 double-blind randomized trials [</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="25992" xml_f="25993" txt_i="12126" txt_f="12127">4</offsets></xref><offsets xml_i="26000" xml_f="26454" txt_i="12127" txt_f="12581">] demonstrated that these were equally distributed across all doses tested. Out of 707 patients 13 (1.8%) reported side effects, 4 of which reported GI-related adverse events. The study protocol considered bioequivalence to be acceptable when the 90% confidence interval was between 75 – 133% based on a large body of bioequivalence studies comparing generic formulations of 400 mg ibuprofen with the reference formulation (Brufen 400 mg in most cases) [</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="26485" xml_f="26486" txt_i="12581" txt_f="12582">5</offsets></xref><offsets xml_i="26493" xml_f="26512" txt_i="12582" txt_f="12601">]. Additional file </offsets><xref ref-type="supplementary-material" rid="S1"><offsets xml_i="26561" xml_f="26562" txt_i="12601" txt_f="12602">1</offsets></xref><offsets xml_i="26569" xml_f="26634" txt_i="12602" txt_f="12667"> displays the results from these studies, illustrating that the C</offsets><sub><offsets xml_i="26639" xml_f="26643" txt_i="12667" txt_f="12671">max </offsets></sub><offsets xml_i="26649" xml_f="26711" txt_i="12671" txt_f="12733">of generic formulations varies substantially from 28.7 (Motrin</offsets><sup><offsets xml_i="26716" xml_f="26718" txt_i="12733" txt_f="12735">® </offsets></sup><offsets xml_i="26724" xml_f="26746" txt_i="12735" txt_f="12757">to 43.3 (Ibuprofen 400</offsets><sup><offsets xml_i="26751" xml_f="26753" txt_i="12757" txt_f="12759">® </offsets></sup><offsets xml_i="26759" xml_f="26766" txt_i="12759" txt_f="12766">Stada).</offsets></p><p><offsets xml_i="26773" xml_f="26774" txt_i="12767" txt_f="12768">C</offsets><sub><offsets xml_i="26779" xml_f="26783" txt_i="12768" txt_f="12772">max </offsets></sub><offsets xml_i="26789" xml_f="26996" txt_i="12772" txt_f="12979">values reported for the present study proved to be within the range of the wide (75 – 133%) but as well within the narrow confidence interval (80 – 125%) and are compatible with the other studies conducted [</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="27027" xml_f="27028" txt_i="12979" txt_f="12980">5</offsets></xref><offsets xml_i="27035" xml_f="27107" txt_i="12980" txt_f="13052">], including the data of a recently published report by Bienert et al. [</offsets><xref ref-type="bibr" rid="B6"><offsets xml_i="27138" xml_f="27139" txt_i="13052" txt_f="13053">6</offsets></xref><offsets xml_i="27146" xml_f="27148" txt_i="13053" txt_f="13055">].</offsets></p></sec><sec><title><offsets xml_i="27170" xml_f="27202" txt_i="13057" txt_f="13089">Rate and extent of absorption (C</offsets><sub><offsets xml_i="27207" xml_f="27211" txt_i="13089" txt_f="13093">max </offsets></sub><offsets xml_i="27217" xml_f="27222" txt_i="13093" txt_f="13098">and t</offsets><sub><offsets xml_i="27227" xml_f="27230" txt_i="13098" txt_f="13101">max</offsets></sub><offsets xml_i="27236" xml_f="27237" txt_i="13101" txt_f="13102">)</offsets></title><p><offsets xml_i="27248" xml_f="27351" txt_i="13103" txt_f="13206">A quick release of ibuprofen in the gastrointestinal tract following oral administration is desirable [</offsets><xref ref-type="bibr" rid="B7"><offsets xml_i="27382" xml_f="27383" txt_i="13206" txt_f="13207">7</offsets></xref><offsets xml_i="27390" xml_f="27811" txt_i="13207" txt_f="13628">] to achieve rapid pain relief and to avoid overdosing due to multiple ingestions based on a prolonged onset of action. As serum concentrations of ibuprofen and its analgesic effect are highly correlated, rapid ibuprofen absorption is the sole prerequisite for the quick onset of its action. Because its membrane permeability approaches up to 100% dissolution of the tablet becomes the rate limiting step for absorption [</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="27842" xml_f="27843" txt_i="13628" txt_f="13629">8</offsets></xref><offsets xml_i="27850" xml_f="27998" txt_i="13629" txt_f="13777">]. A more rapid pain relief could translate in higher patient satisfaction and less danger of repeated ibuprofen intake due to slow onset of action.</offsets></p><p><offsets xml_i="28005" xml_f="28057" txt_i="13778" txt_f="13830">It has been shown in the present study that Eudorlin</offsets><sup><offsets xml_i="28062" xml_f="28064" txt_i="13830" txt_f="13832">® </offsets></sup><offsets xml_i="28070" xml_f="28343" txt_i="13832" txt_f="14105">extra tablets are rapidly dissolved in vitro resulting in 99% dissolution after only 5 minutes. In comparison it took 30 and 45 min respectively for the two reference formulations to achieve a similar degree of dissolution. This observation is compatible with the faster (t</offsets><sub><offsets xml_i="28348" xml_f="28351" txt_i="14105" txt_f="14108">max</offsets></sub><offsets xml_i="28357" xml_f="28398" txt_i="14108" txt_f="14149">) and higher peak plasma concentration (C</offsets><sub><offsets xml_i="28403" xml_f="28406" txt_i="14149" txt_f="14152">max</offsets></sub><offsets xml_i="28412" xml_f="28570" txt_i="14152" txt_f="14310">) observed in the present cross-over study in healthy volunteers. The values obtained did on the other hand not trespass the predefined acceptance range for C</offsets><sub><offsets xml_i="28575" xml_f="28579" txt_i="14310" txt_f="14314">max </offsets></sub><offsets xml_i="28585" xml_f="28658" txt_i="14314" txt_f="14387">as outlines above, thus not questioning the assumption of bioequivalence.</offsets></p></sec></sec><sec><title><offsets xml_i="28686" xml_f="28696" txt_i="14390" txt_f="14400">Conclusion</offsets></title><p><offsets xml_i="28707" xml_f="28893" txt_i="14401" txt_f="14587">Statistical analyses of primary parameters provided evidence for the therapeutic equivalence of the three ibuprofen formulations: the 90%-confidence intervals for the comparison Eudorlin</offsets><sup><offsets xml_i="28898" xml_f="28900" txt_i="14587" txt_f="14589">® </offsets></sup><offsets xml_i="28906" xml_f="28919" txt_i="14589" txt_f="14602">extra/Nurofen</offsets><sup><offsets xml_i="28924" xml_f="28926" txt_i="14602" txt_f="14604">® </offsets></sup><offsets xml_i="28932" xml_f="28950" txt_i="14604" txt_f="14622">forte and Eudorlin</offsets><sup><offsets xml_i="28955" xml_f="28957" txt_i="14622" txt_f="14624">® </offsets></sup><offsets xml_i="28963" xml_f="28977" txt_i="14624" txt_f="14638">extra/Migränin</offsets><sup><offsets xml_i="28982" xml_f="28984" txt_i="14638" txt_f="14640">® </offsets></sup><offsets xml_i="28990" xml_f="29062" txt_i="14640" txt_f="14712">were within the predefined acceptance range of 0.80 – 1.25 for both, AUC</offsets><sub><offsets xml_i="29067" xml_f="29077" txt_i="14712" txt_f="14722">0-t(last) </offsets></sub><offsets xml_i="29083" xml_f="29090" txt_i="14722" txt_f="14729">and AUC</offsets><sub><offsets xml_i="29095" xml_f="29099" txt_i="14729" txt_f="14733">0-∞ </offsets></sub><offsets xml_i="29105" xml_f="29171" txt_i="14733" txt_f="14799">and within the acceptance range of 0.75 – 1.33 for the parameter C</offsets><sub><offsets xml_i="29176" xml_f="29179" txt_i="14799" txt_f="14802">max</offsets></sub><offsets xml_i="29185" xml_f="29337" txt_i="14802" txt_f="14954">. Peak plasma concentration was however higher and the time to peak plasma concentration shorter, compatible with a more rapid pain relief with Eudorlin</offsets><sup><offsets xml_i="29342" xml_f="29344" txt_i="14954" txt_f="14956">® </offsets></sup><offsets xml_i="29350" xml_f="29509" txt_i="14956" txt_f="15115">extra. All three formulations were well tolerated. The only adverse event with a possible relation to the study drug was reported by one subject after Migränin</offsets><sup><offsets xml_i="29514" xml_f="29516" txt_i="15115" txt_f="15117">® </offsets></sup><offsets xml_i="29522" xml_f="29531" txt_i="15117" txt_f="15126">exposure.</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="29572" xml_f="29579" txt_i="15128" txt_f="15135">Methods</offsets></title><sec><title><offsets xml_i="29599" xml_f="29634" txt_i="15136" txt_f="15171">Study design and inclusion criteria</offsets></title><p><sup><offsets xml_i="29650" xml_f="29652" txt_i="15172" txt_f="15174">2 </offsets></sup><offsets xml_i="29658" xml_f="29930" txt_i="15174" txt_f="15446">and had provided written informed consent prior to study participation. Women of childbearing age had to be negative on a pregnancy test and had to agree to be either sexually inactive for 30 days prior to study participation or use an appropriate method of contraception.</offsets></p></sec><sec><title><offsets xml_i="29952" xml_f="29964" txt_i="15448" txt_f="15460">Test product</offsets></title><p><offsets xml_i="29975" xml_f="30017" txt_i="15461" txt_f="15503">Film coated tablets of ibuprofen (Eudorlin</offsets><sup><offsets xml_i="30022" xml_f="30024" txt_i="15503" txt_f="15505">® </offsets></sup><offsets xml_i="30030" xml_f="30170" txt_i="15505" txt_f="15645">extra for oral administration, batch number 62020, expiry date 05/2009) were tested against two reference formulations of ibuprofen: Nurofen</offsets><sup><offsets xml_i="30175" xml_f="30177" txt_i="15645" txt_f="15647">® </offsets></sup><offsets xml_i="30183" xml_f="30273" txt_i="15647" txt_f="15737">forte (Ibuprofen 400 mg coated tablets, batch number 13J, expiry date 06/2009 and Migränin</offsets><sup><offsets xml_i="30278" xml_f="30280" txt_i="15737" txt_f="15739">® </offsets></sup><offsets xml_i="30286" xml_f="30456" txt_i="15739" txt_f="15909">(Ibuprofen 400 mg coated tablets, batch number 12J, expiry date 06/2008). Dissolution testing was performed at pharm-analyt Labor GmbH, Baden, Austria between February 23</offsets><sup><offsets xml_i="30461" xml_f="30464" txt_i="15909" txt_f="15912">rd </offsets></sup><offsets xml_i="30470" xml_f="30482" txt_i="15912" txt_f="15924">and March 15</offsets><sup><offsets xml_i="30487" xml_f="30490" txt_i="15924" txt_f="15927">th </offsets></sup><offsets xml_i="30496" xml_f="30527" txt_i="15927" txt_f="15958">2007 using a HPLC-UV technique.</offsets></p></sec><sec><title><offsets xml_i="30549" xml_f="30567" txt_i="15960" txt_f="15978">Treatment protocol</offsets></title><p><offsets xml_i="30578" xml_f="30705" txt_i="15979" txt_f="16106">A three sequence cross-over design, allowed for the comparison of different subject sequences: 1) Subjects who received Nurofen</offsets><sup><offsets xml_i="30710" xml_f="30712" txt_i="16106" txt_f="16108">® </offsets></sup><offsets xml_i="30718" xml_f="30793" txt_i="16108" txt_f="16183">forte (A) during periods 1 and 2 compared to subjects who received Eudorlin</offsets><sup><offsets xml_i="30798" xml_f="30800" txt_i="16183" txt_f="16185">® </offsets></sup><offsets xml_i="30806" xml_f="30898" txt_i="16185" txt_f="16277">extra (E) during these periods (1 and 2) (sequence AE/EA); 2) Subjects who received Migränin</offsets><sup><offsets xml_i="30903" xml_f="30905" txt_i="16277" txt_f="16279">® </offsets></sup><offsets xml_i="30911" xml_f="30979" txt_i="16279" txt_f="16347">(B) during period 2 and 3 compared to subjects who received Eudorlin</offsets><sup><offsets xml_i="30984" xml_f="30986" txt_i="16347" txt_f="16349">® </offsets></sup><offsets xml_i="30992" xml_f="31151" txt_i="16349" txt_f="16508">extra (E) during these periods (2 and 3) (sequence EB/BE). The study consisted of three treatment phases separated by wash-out periods of 7 to 10 days (Figure </offsets><xref ref-type="fig" rid="F4"><offsets xml_i="31181" xml_f="31182" txt_i="16508" txt_f="16509">4</offsets></xref><offsets xml_i="31189" xml_f="32007" txt_i="16509" txt_f="17327">). At least 12 h before each treatment period the subjects were admitted to the site. After an overnight fasting of at least 10 h subjects were administered 400 mg ibuprofen in sitting position between 8 and 9 a.m. (time point 0). Blood samples (6 ml each) were collected from all subjects 12 min prior to dosing and at 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 10.0, 12.0, 16.0 and 24.0 hours after drug administration. Patients were observed for a total of 36 h (12 h prior until 24 h after drug administration). The blood samples were collected in heparinised tubes and cooled immediately in an ice bath and centrifuged at 3500 r.p.m. under refrigeration to obtain plasma. Immediately after centrifugation the plasma was homogenized, the tubes capped and stored frozen at -20°C.</offsets></p><fig position="float" id="F4"><label><offsets xml_i="32048" xml_f="32056" txt_i="17328" txt_f="17336">Figure 4</offsets></label><caption><p><bold><offsets xml_i="32082" xml_f="32156" txt_i="17336" txt_f="17410">Allocation of subjects to the appropriate sequence groups during the study</offsets></bold><offsets xml_i="32163" xml_f="32222" txt_i="17410" txt_f="17469">. S: Sequence groups; A: subjects receiving drug A (Nurofen</offsets><sup><offsets xml_i="32227" xml_f="32229" txt_i="17469" txt_f="17471">® </offsets></sup><offsets xml_i="32235" xml_f="32281" txt_i="17471" txt_f="17517">forte), B: subjects receiving drug B (Migränin</offsets><sup><offsets xml_i="32286" xml_f="32287" txt_i="17517" txt_f="17518">®</offsets></sup><offsets xml_i="32293" xml_f="32325" txt_i="17518" txt_f="17550">, E: subjects receiving Eudorlin</offsets><sup><offsets xml_i="32330" xml_f="32332" txt_i="17550" txt_f="17552">® </offsets></sup><offsets xml_i="32338" xml_f="32344" txt_i="17552" txt_f="17558">extra.</offsets></p></caption><graphic xlink:href="1471-2210-8-18-4"></graphic></fig></sec><sec><title><offsets xml_i="32431" xml_f="32451" txt_i="17560" txt_f="17580">Clinical examination</offsets></title><p><offsets xml_i="32462" xml_f="33212" txt_i="17581" txt_f="18331">Personal data, medical history, physical examinations (height, weight, 12-lead ECG), vital signs (blood pressure, heart rate, temperature) and laboratory tests were obtained during the screening phase. During each treatment period, vital signs and adverse events were recorded. Clinical safety parameters included a general medical examination, heart rate and blood pressure (sitting position) and the documentation of adverse events. Clinical laboratory safety was assessed with clinical chemistry, haematology, urinalysis, pregnancy test, HIV, HbsAg and HCV screening, urine drug screening and an alcohol breath test. Within a 7 day time frame after last blood sampling an ECG, clinical laboratory parameters and physical examination were repeated.</offsets></p></sec><sec><title><offsets xml_i="33234" xml_f="33278" txt_i="18333" txt_f="18377">Analytical method and chromatographic system</offsets></title><p><offsets xml_i="33289" xml_f="33345" txt_i="18378" txt_f="18434">Determination was conducted considering GLP-guidelines [</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="33376" xml_f="33377" txt_i="18434" txt_f="18435">9</offsets></xref><offsets xml_i="33384" xml_f="33486" txt_i="18435" txt_f="18537">]. Procedure of validation and acceptance criteria were based on the rules and guidelines of the FDA [</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="33518" xml_f="33520" txt_i="18537" txt_f="18539">10</offsets></xref><offsets xml_i="33527" xml_f="34061" txt_i="18539" txt_f="19073">] and of the ICH Consensus Guidelines. Pre-study validation of the method was performed by documentation of specificity, linearity, limit of quantification, precision and accuracy. Furthermore recovery rate and stability of ibuprofen in plasma samples were investigated. For in-study validation each run contained samples for the calculation of standard curves; quality control samples and the samples of the subjects. The run was accepted, if no more than two of six quality control samples were outside ± 15% from the nominal value.</offsets></p><p><offsets xml_i="34068" xml_f="34156" txt_i="19074" txt_f="19162">Determination of ibuprofen was performed using HPLC method with fluorescence detection [</offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="34188" xml_f="34190" txt_i="19162" txt_f="19164">11</offsets></xref><offsets xml_i="34197" xml_f="34498" txt_i="19164" txt_f="19465">]. A Merck-Hitachi L-7485 was used for detection of ibuprofen (excitation 225 nm, emission 290 nm). Chromatographic separation was carries out using a Luna 5 μC18(2) 100A, 50 × 2.0 mm (Phenomenex, USA). The mobile phase was 35% 0.02 molar phosphoric acid: 65% MeOH (v/v). The flow rate was 1.0 ml/min.</offsets></p><p><offsets xml_i="34505" xml_f="34783" txt_i="19466" txt_f="19744">A sample volume of 250 μl was analyzed and a volume of 10 μl injected onto the chromatographic column. The method was validated between 0.200 and 75.0 μg/ml. In this study the retention time was 1.5 min. The blank sample showed no peaks in the retention time window of interest.</offsets></p><p><offsets xml_i="34790" xml_f="34821" txt_i="19745" txt_f="19776">The assay showed an acceptable </offsets><italic><offsets xml_i="34829" xml_f="34839" txt_i="19776" txt_f="19786">linearity </offsets></italic><offsets xml_i="34848" xml_f="34984" txt_i="19786" txt_f="19922">over a concentration range from 0.200 to 75.0 μg/ml (r ≥ 0.99, n = 8). The limit of detection defined as baseline noise was 0.206 μg/l. </offsets><italic><offsets xml_i="34992" xml_f="35005" txt_i="19922" txt_f="19935">Specificity: </offsets></italic><offsets xml_i="35014" xml_f="35158" txt_i="19935" txt_f="20079">There were no interfering peaks for the endogenous compound for the blank plasma at the retention time of ibuprofen (1.5 min.). The inter-batch </offsets><italic><offsets xml_i="35166" xml_f="35176" txt_i="20079" txt_f="20089">precision </offsets></italic><offsets xml_i="35185" xml_f="35336" txt_i="20089" txt_f="20240">was between 9.96% for 0.500 μg/ml and 6.35% for 63.8 μg/ml. The within-batch precision was between 1.56% for 0.206 μg/ml and 5.83% for 75.0 μg/ml. The </offsets><italic><offsets xml_i="35344" xml_f="35353" txt_i="20240" txt_f="20249">accuracy </offsets></italic><offsets xml_i="35362" xml_f="35603" txt_i="20249" txt_f="20490">(bias) for ibuprofen was expressed as a percent deviation of observed plasma concentration from theoretical concentration (0.5, 5.51 and 63.8 μg/ml). The accuracy ranged from 1.3% (0.500 μg/ml) to 4.5% (5.51 μg/ml). For the determination of </offsets><italic><offsets xml_i="35611" xml_f="35620" txt_i="20490" txt_f="20499">recovery </offsets></italic><offsets xml_i="35629" xml_f="35921" txt_i="20499" txt_f="20791">peak areas determined following analysis of calibration standards with concentrations of 0.5, 5.51 and 63.8 μg/ml were compared with data obtained by direct injection of aqueous solutions of these concentrations. The mean recovery of ibuprofen from spiked plasma samples was on average 92.2%.</offsets></p></sec><sec><title><offsets xml_i="35943" xml_f="35953" txt_i="20793" txt_f="20803">Statistics</offsets></title><p><offsets xml_i="35964" xml_f="36071" txt_i="20804" txt_f="20911">Sample size was based on a intra-individual CV of 26% based on a previous bioavailability study of Eudorlin</offsets><sup><offsets xml_i="36076" xml_f="36078" txt_i="20911" txt_f="20913">® </offsets></sup><offsets xml_i="36084" xml_f="36168" txt_i="20913" txt_f="20997">extra (Clinical trial report BCBe/02/Ibu-BV-001) and data from Blume and Mutschler [</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="36199" xml_f="36200" txt_i="20997" txt_f="20998">5</offsets></xref><offsets xml_i="36207" xml_f="36605" txt_i="20998" txt_f="21396">]. For a total of 36 subjects (2 × 18) the power to detect bioequivalence was 96% assuming a true ratio of 0.95, and 98% assuming a true ratio of 1.05 (calculations based on equivalence limits of 0.75 and 1.33). As bioequivalence had to be shown with 2 reference products sample size was adjusted to 3 × 18 (54) subjects. Therefore 60 patients were included to allow a drop-out of 10% (6 subjects).</offsets></p><p><offsets xml_i="36612" xml_f="36670" txt_i="21397" txt_f="21455">The statistical analyses were performed by using SAS 8.2 [</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="36702" xml_f="36704" txt_i="21455" txt_f="21457">12</offsets></xref><offsets xml_i="36711" xml_f="37098" txt_i="21457" txt_f="21844">]. The primary pharmacokinetic parameters after logarithmic transformation (multiplicative model) were subjected to an analysis of variance (ANOVA) with the factors SEQUENCE, SUBJECT nested within SEQUENCE, PERIOD and FORM (drug formulation) using a general linear model procedure. For assessment of bioequivalence 90%-confidence intervals for the formulation ratio in the parameters AUC</offsets><sub><offsets xml_i="37103" xml_f="37105" txt_i="21844" txt_f="21846">t </offsets></sub><offsets xml_i="37111" xml_f="37155" txt_i="21846" txt_f="21890">(calculated using the trapezoidal rule), AUC</offsets><sub><offsets xml_i="37160" xml_f="37162" txt_i="21890" txt_f="21892">∞ </offsets></sub><offsets xml_i="37168" xml_f="37193" txt_i="21892" txt_f="21917">(calculated as sum of AUC</offsets><sub><offsets xml_i="37198" xml_f="37200" txt_i="21917" txt_f="21919">t </offsets></sub><offsets xml_i="37206" xml_f="37272" txt_i="21919" txt_f="21985">and the extrapolated area using the last measured concentration [C</offsets><sub><offsets xml_i="37277" xml_f="37283" txt_i="21985" txt_f="21991">(last)</offsets></sub><offsets xml_i="37289" xml_f="37346" txt_i="21991" txt_f="22048">] and the elimination half life by taking the formula: [C</offsets><sub><offsets xml_i="37351" xml_f="37358" txt_i="22048" txt_f="22055">(last) </offsets></sub><offsets xml_i="37364" xml_f="37367" txt_i="22055" txt_f="22058">× t</offsets><sub><offsets xml_i="37372" xml_f="37375" txt_i="22058" txt_f="22061">1/2</offsets></sub><offsets xml_i="37381" xml_f="37394" txt_i="22061" txt_f="22074">/ln2]), and C</offsets><sub><offsets xml_i="37399" xml_f="37403" txt_i="22074" txt_f="22078">max </offsets></sub><offsets xml_i="37409" xml_f="37612" txt_i="22078" txt_f="22281">(directly obtained from measured values) of ibuprofen were calculated using the ln-transformed data. Bioequivalence was accepted if the calculated 90%-confidence intervals were within 0.80 – 1.25 for AUC</offsets><sub><offsets xml_i="37617" xml_f="37619" txt_i="22281" txt_f="22283">t </offsets></sub><offsets xml_i="37625" xml_f="37653" txt_i="22283" txt_f="22311">and within 0.75 – 1.33 for C</offsets><sub><offsets xml_i="37658" xml_f="37661" txt_i="22311" txt_f="22314">max</offsets></sub><offsets xml_i="37667" xml_f="37790" txt_i="22314" txt_f="22437">. Possible side effects of the study medication and any adverse events were listed. Time of maximum plasma concentration (t</offsets><sub><offsets xml_i="37795" xml_f="37798" txt_i="22437" txt_f="22440">max</offsets></sub><offsets xml_i="37804" xml_f="37923" txt_i="22440" txt_f="22559">) was directly obtained from measured values and compared using the two samples Wilcoxon test. Elimination half life (t</offsets><sub><offsets xml_i="37928" xml_f="37931" txt_i="22559" txt_f="22562">1/2</offsets></sub><offsets xml_i="37937" xml_f="38081" txt_i="22562" txt_f="22706">) was calculated from concentrations of the elimination phase using semi-log transformed data and linear regression was documented individually.</offsets></p></sec></sec><sec><title><offsets xml_i="38109" xml_f="38131" txt_i="22709" txt_f="22731">Authors' contributions</offsets></title><p><offsets xml_i="38142" xml_f="38343" txt_i="22732" txt_f="22933">AG was the principal investigator at IFE Human Pharmacology SRL and was responsible for planning and conducting the study. PB drafted the manuscript. All authors read and approved the final manuscript.</offsets></p></sec><sec sec-type="supplementary-material"><title><offsets xml_i="38399" xml_f="38421" txt_i="22935" txt_f="22957">Supplementary Material</offsets></title><supplementary-material content-type="local-data" id="S1"><caption><title><offsets xml_i="38503" xml_f="38520" txt_i="22958" txt_f="22975">Additional file 1</offsets></title><p><bold><offsets xml_i="38537" xml_f="38584" txt_i="22976" txt_f="23023">Cmax values from various bioequivalence studies</offsets></bold></p></caption><media xlink:href="1471-2210-8-18-S1.doc" mimetype="application" mime-subtype="msword"><caption><p><offsets xml_i="38704" xml_f="38723" txt_i="23024" txt_f="23043">Click here for file</offsets></p></caption></media></supplementary-material></sec></body><back><ack><sec><title>Acknowledgements</title><p>The study was sponsored by Berlin-Chemie AG, Berlin, Germany and conducted by IFE Human Pharmacology SRL in Timisoara, Romania. Dissolution testing was done by pharm-analyt Labor GmbH, Baden, Austria.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="other"><article-title>The story of ibuprofen</article-title><ext-link ext-link-type="uri" xlink:href="http://www.ibuprofen-foundation.com/"></ext-link></citation></ref><ref id="B2"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Frölich</surname><given-names>JC</given-names></name><name><surname>Fricker</surname><given-names>RM</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Frölich JC, Kirch W</surname></name></person-group><article-title>[Pain therapy and analgetics-antipyretics (Nonsteroidal antirheumatic drugs – NSAR)]</article-title><source>Praktische Arzneitherapie</source><year>2006</year><edition>4</edition><publisher-name>Heidelberg: Springer</publisher-name><fpage>675</fpage><lpage>706</lpage></citation></ref><ref id="B3"><citation citation-type="other"><article-title>Note for Guidance on the Investigation Bioavailability and Bioequivalence (CPMP/EWP/QWP/1401/98)</article-title></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Furey</surname><given-names>SA</given-names></name><name><surname>Waksman</surname><given-names>JA</given-names></name><name><surname>Dash</surname><given-names>BH</given-names></name></person-group><article-title>Nonprescription ibuprofen: side effect profile</article-title><source>Pharmacotherapy</source><year>1992</year><volume>12</volume><fpage>403</fpage><lpage>407</lpage><pub-id pub-id-type="pmid">1437701</pub-id></citation></ref><ref id="B5"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Blume</surname><given-names>H</given-names></name><name><surname>Mutschler</surname><given-names>E</given-names></name></person-group><source>Bioäquivalenz, Qualitätsbewertung wirkstoffgleicher Fertigarzneimittel</source><year>1996</year><publisher-name>Frankfurt/Main – Eschborn: Govi-Verlag Pharmazeutischer Verlag</publisher-name></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bienert</surname><given-names>A</given-names></name><name><surname>Szkutnik-Fiedler</surname><given-names>D</given-names></name><name><surname>Dyderski</surname><given-names>S</given-names></name><name><surname>Grzeskowiak</surname><given-names>E</given-names></name><name><surname>Drobnik</surname><given-names>L</given-names></name><name><surname>Wolc</surname><given-names>A</given-names></name><name><surname>Slawiniska</surname><given-names>U</given-names></name></person-group><article-title>Comparative bioavailability study of two ibuprofen preparations after oral administration in healthy volunteers</article-title><source>Arzneimittel-Forschung</source><year>2006</year><volume>56</volume><fpage>647</fpage><lpage>651</lpage><pub-id pub-id-type="pmid">17063640</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Laska</surname><given-names>EM</given-names></name><name><surname>Sunshine</surname><given-names>A</given-names></name><name><surname>Marrero</surname><given-names>I</given-names></name><name><surname>Olson</surname><given-names>N</given-names></name><name><surname>Siegel</surname><given-names>C</given-names></name><name><surname>McCormick</surname><given-names>N</given-names></name></person-group><article-title>The correlation between blood levels of ibuprofen and clinical analgesic response</article-title><source>Clin Pharmacol Ther</source><year>1986</year><volume>40</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">3522030</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Newa</surname><given-names>M</given-names></name><name><surname>Bhandari</surname><given-names>KH</given-names></name><name><surname>Kim</surname><given-names>JO</given-names></name><name><surname>Im</surname><given-names>JS</given-names></name><name><surname>Kim</surname><given-names>JA</given-names></name><name><surname>Yoo</surname><given-names>BK</given-names></name><name><surname>Woo</surname><given-names>JS</given-names></name><name><surname>Choi</surname><given-names>HG</given-names></name><name><surname>Yong</surname><given-names>CS</given-names></name></person-group><article-title>Enhancement of solubility, dissolution and bioavailability of ibuprofen in solid dispersion systems</article-title><source>Chem Pharm Bull (Tokyo)</source><year>2008</year><volume>56</volume><fpage>569</fpage><lpage>574</lpage><pub-id pub-id-type="pmid">18379109</pub-id></citation></ref><ref id="B9"><citation citation-type="other"><person-group person-group-type="author"><collab>GLP</collab></person-group><article-title>Principles of Good Laboratory Practice as specified by national (German Chemicals Law, Annex 1, 20 June 2002) and international (OECD, Paris, 1998; EC Directive 2004/10/EC, 11. February 2004)</article-title></citation></ref><ref id="B10"><citation citation-type="other"><article-title>U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM). Guidance for Industry Bioanalytical Method Validation</article-title><ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/cder/guidance/index.htm"></ext-link></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sochor</surname><given-names>J</given-names></name><name><surname>Klimes</surname><given-names>J</given-names></name><name><surname>Sedlacek</surname><given-names>J</given-names></name><name><surname>Zahradnicek</surname><given-names>M</given-names></name></person-group><article-title>Determination of ibuprofen in erythrocytes and plasma by high performance liquid chromatography</article-title><source>J Pharm Biomed Anal</source><year>1995</year><volume>13</volume><fpage>899</fpage><lpage>903</lpage><pub-id pub-id-type="pmid">8562614</pub-id></citation></ref><ref id="B12"><citation citation-type="book"><person-group person-group-type="author"><collab>SAS8.2</collab></person-group><article-title>SAS<sup>® </sup>software</article-title><source>Release 82 edition</source><year>2001</year><publisher-name>Cary NC: SAS Institute Inc</publisher-name></citation></ref></ref-list></back></article>